auto-fix: strip 73 broken wiki links

Pipeline auto-fixer: removed [[ ]] brackets from links
that don't resolve to existing claims in the knowledge base.

domains/energy/arctic and nuclear-powered data centers solve the same power and cooling constraints as orbital compute without launch costs radiation or bandwidth limitations.md

@@ -9,14 +9,14 @@ secondary_domains:
   - space-development
   - critical-systems
 depends_on:
-  - "AI compute demand is creating a terrestrial power crisis with 140 GW of new data center load against grid infrastructure already projected to fall 6 GW short by 2027"
+- AI compute demand is creating a terrestrial power crisis with 140 GW of new data center load against grid infrastructure already projected to fall 6 GW short by 2027
-  - "space-based computing at datacenter scale is blocked by thermal physics because radiative cooling in vacuum requires surface areas that grow faster than compute density"
+- space-based computing at datacenter scale is blocked by thermal physics because radiative cooling in vacuum requires surface areas that grow faster than compute density
 related:
-  - "orbital compute hardware cannot be serviced making every component either radiation hardened redundant or disposable with failed hardware becoming debris or requiring expensive deorbit"
+- orbital compute hardware cannot be serviced making every component either radiation hardened redundant or disposable with failed hardware becoming debris or requiring expensive deorbit
-  - "AI datacenter power demand creates a 5 10 year infrastructure lag because grid construction and interconnection cannot match the pace of chip design cycles"
+- AI datacenter power demand creates a 5 10 year infrastructure lag because grid construction and interconnection cannot match the pace of chip design cycles
 reweave_edges:
-  - "orbital compute hardware cannot be serviced making every component either radiation hardened redundant or disposable with failed hardware becoming debris or requiring expensive deorbit|related|2026-04-04"
+- orbital compute hardware cannot be serviced making every component either radiation hardened redundant or disposable with failed hardware becoming debris or requiring expensive deorbit|related|2026-04-04
-  - "AI datacenter power demand creates a 5 10 year infrastructure lag because grid construction and interconnection cannot match the pace of chip design cycles|related|2026-04-04"
+- AI datacenter power demand creates a 5 10 year infrastructure lag because grid construction and interconnection cannot match the pace of chip design cycles|related|2026-04-04
 ---
 
 # Arctic and nuclear-powered data centers solve the same power and cooling constraints as orbital compute without launch costs radiation or bandwidth limitations
@@ -47,4 +47,4 @@ Relevant Notes:
 - [[space-based computing at datacenter scale is blocked by thermal physics because radiative cooling in vacuum requires surface areas that grow faster than compute density]] — the physics constraint giving terrestrial alternatives their advantage
 
 Topics:
-- [[space exploration and development]]
+- space exploration and development

domains/health/CMS is creating AI-specific reimbursement codes which will formalize a two-speed adoption system where proven AI applications get payment parity while experimental ones remain in cash-pay limbo.md

@@ -6,12 +6,12 @@ confidence: likely
 source: "Bessemer Venture Partners, State of Health AI 2026 (bvp.com/atlas/state-of-health-ai-2026)"
 created: 2026-03-07
 supports:
-  - "consumer willingness to pay out of pocket for AI enhanced care is outpacing reimbursement creating a cash pay adoption pathway that bypasses traditional payer gatekeeping"
+- consumer willingness to pay out of pocket for AI enhanced care is outpacing reimbursement creating a cash pay adoption pathway that bypasses traditional payer gatekeeping
 reweave_edges:
-  - "consumer willingness to pay out of pocket for AI enhanced care is outpacing reimbursement creating a cash pay adoption pathway that bypasses traditional payer gatekeeping|supports|2026-03-28"
+- consumer willingness to pay out of pocket for AI enhanced care is outpacing reimbursement creating a cash pay adoption pathway that bypasses traditional payer gatekeeping|supports|2026-03-28
-  - "tempo pilot creates medicare digital health pathway while medicaid coverage contracts|related|2026-04-04"
+- tempo pilot creates medicare digital health pathway while medicaid coverage contracts|related|2026-04-04
 related:
-  - "tempo pilot creates medicare digital health pathway while medicaid coverage contracts"
+- tempo pilot creates medicare digital health pathway while medicaid coverage contracts
 ---
 
 # CMS is creating AI-specific reimbursement codes which will formalize a two-speed adoption system where proven AI applications get payment parity while experimental ones remain in cash-pay limbo
@@ -33,12 +33,12 @@ The investment implication: companies positioned at the category I boundary —
 ---
 
 ### Additional Evidence (extend)
-*Source: [[2025-12-05-fda-tempo-pilot-cms-access-digital-health-ckm]] | Added: 2026-03-31*
+*Source: 2025-12-05-fda-tempo-pilot-cms-access-digital-health-ckm | Added: 2026-03-31*
 
 TEMPO + CMS ACCESS model formalizes a two-speed system at an earlier stage: pre-clearance devices get Medicare reimbursement through ACCESS while collecting evidence, versus cleared devices with standard coverage. This creates a research-to-reimbursement pathway that didn't exist before January 2026, but scale is limited to ~10 manufacturers per clinical area.
 
 ### Additional Evidence (extend)
-*Source: [[2026-04-01-fda-tempo-cms-access-selection-pending-july-performance-period]] | Added: 2026-04-01*
+*Source: 2026-04-01-fda-tempo-cms-access-selection-pending-july-performance-period | Added: 2026-04-01*
 
 TEMPO + ACCESS coordination demonstrates the two-speed system in practice: Medicare beneficiaries (65+) gain access to FDA-approved digital health devices through TEMPO while Medicaid populations face coverage contraction. The ACCESS model's July 1, 2026 performance period start creates a defined timeline for when Medicare digital health infrastructure becomes operational, while no equivalent pathway exists for Medicaid populations.
 

domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md

@@ -6,22 +6,22 @@ created: 2026-02-17
 source: "Grand View Research GLP-1 market analysis 2025; CNBC Lilly/Novo earnings reports; PMC weight regain meta-analyses 2025; KFF Medicare GLP-1 cost modeling; Epic Research discontinuation data"
 confidence: likely
 related:
-  - "federal budget scoring methodology systematically undervalues preventive interventions because 10 year window excludes long term savings"
+- federal budget scoring methodology systematically undervalues preventive interventions because 10 year window excludes long term savings
-  - "glp 1 multi organ protection creates compounding value across kidney cardiovascular and metabolic endpoints"
+- glp 1 multi organ protection creates compounding value across kidney cardiovascular and metabolic endpoints
-  - "GLP 1 cost evidence accelerates value based care adoption by proving that prevention first interventions generate net savings under capitation within 24 months"
+- GLP 1 cost evidence accelerates value based care adoption by proving that prevention first interventions generate net savings under capitation within 24 months
-  - "GLP-1 access structure is inverted relative to clinical need because populations with highest obesity prevalence and cardiometabolic risk face the highest barriers creating an equity paradox where the most effective cardiovascular intervention will disproportionately benefit already-advantaged populations"
+- GLP-1 access structure is inverted relative to clinical need because populations with highest obesity prevalence and cardiometabolic risk face the highest barriers creating an equity paradox where the most effective cardiovascular intervention will disproportionately benefit already-advantaged populations
-  - "GLP-1 receptor agonists show 20% individual-level mortality reduction but are projected to reduce US population mortality by only 3.5% by 2045 because access barriers and adherence constraints create a 20-year lag between clinical efficacy and population-level detectability"
+- GLP-1 receptor agonists show 20% individual-level mortality reduction but are projected to reduce US population mortality by only 3.5% by 2045 because access barriers and adherence constraints create a 20-year lag between clinical efficacy and population-level detectability
-  - "semaglutide reduces kidney disease progression 24 percent and delays dialysis creating largest per patient cost savings"
+- semaglutide reduces kidney disease progression 24 percent and delays dialysis creating largest per patient cost savings
 reweave_edges:
-  - "federal budget scoring methodology systematically undervalues preventive interventions because 10 year window excludes long term savings|related|2026-03-31"
+- federal budget scoring methodology systematically undervalues preventive interventions because 10 year window excludes long term savings|related|2026-03-31
-  - "glp 1 multi organ protection creates compounding value across kidney cardiovascular and metabolic endpoints|related|2026-03-31"
+- glp 1 multi organ protection creates compounding value across kidney cardiovascular and metabolic endpoints|related|2026-03-31
-  - "glp 1 persistence drops to 15 percent at two years for non diabetic obesity patients undermining chronic use economics|supports|2026-03-31"
+- glp 1 persistence drops to 15 percent at two years for non diabetic obesity patients undermining chronic use economics|supports|2026-03-31
-  - "GLP 1 cost evidence accelerates value based care adoption by proving that prevention first interventions generate net savings under capitation within 24 months|related|2026-04-04"
+- GLP 1 cost evidence accelerates value based care adoption by proving that prevention first interventions generate net savings under capitation within 24 months|related|2026-04-04
-  - "GLP-1 access structure is inverted relative to clinical need because populations with highest obesity prevalence and cardiometabolic risk face the highest barriers creating an equity paradox where the most effective cardiovascular intervention will disproportionately benefit already-advantaged populations|related|2026-04-04"
+- GLP-1 access structure is inverted relative to clinical need because populations with highest obesity prevalence and cardiometabolic risk face the highest barriers creating an equity paradox where the most effective cardiovascular intervention will disproportionately benefit already-advantaged populations|related|2026-04-04
-  - "GLP-1 receptor agonists show 20% individual-level mortality reduction but are projected to reduce US population mortality by only 3.5% by 2045 because access barriers and adherence constraints create a 20-year lag between clinical efficacy and population-level detectability|related|2026-04-04"
+- GLP-1 receptor agonists show 20% individual-level mortality reduction but are projected to reduce US population mortality by only 3.5% by 2045 because access barriers and adherence constraints create a 20-year lag between clinical efficacy and population-level detectability|related|2026-04-04
-  - "semaglutide reduces kidney disease progression 24 percent and delays dialysis creating largest per patient cost savings|related|2026-04-04"
+- semaglutide reduces kidney disease progression 24 percent and delays dialysis creating largest per patient cost savings|related|2026-04-04
 supports:
-  - "glp 1 persistence drops to 15 percent at two years for non diabetic obesity patients undermining chronic use economics"
+- glp 1 persistence drops to 15 percent at two years for non diabetic obesity patients undermining chronic use economics
 ---
 
 # GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035
@@ -144,24 +144,24 @@ Aon's 192,000+ patient analysis shows the inflationary impact is front-loaded an
 
 
 ### Additional Evidence (challenge)
-*Source: [[2026-03-20-stat-glp1-semaglutide-india-patent-expiry-generics]] | Added: 2026-03-20*
+*Source: 2026-03-20-stat-glp1-semaglutide-india-patent-expiry-generics | Added: 2026-03-20*
 
 India's March 20 2026 patent expiration launched 50+ generic brands at 50-60% price reduction (₹3,000-5,000/month vs ₹8,000-16,000 branded), with analysts projecting 90% price reduction over 5 years. Patents also expire in 2026 in Canada, Brazil, Turkey, China. University of Liverpool shows production costs as low as $3/month. US patents hold until 2031-2033, creating geographic bifurcation where international markets experience deflationary pressure starting 2026 while US remains inflationary through 2033.
 
 ---
 
 ### Additional Evidence (challenge)
-*Source: [[2026-03-21-natco-semaglutide-india-day1-launch-1290]] | Added: 2026-03-21*
+*Source: 2026-03-21-natco-semaglutide-india-day1-launch-1290 | Added: 2026-03-21*
 
 Natco Pharma launched generic semaglutide in India at ₹1,290/month ($15.50) on March 20, 2026, the day the patent expired. This is 90% below innovator pricing and 2-3x lower than analyst projections made days earlier ($40-77/month within a year). 50+ manufacturers from 40+ companies are entering the market, with Sun Pharma, Zydus, Dr. Reddy's, and Eris launching on Day 1. The 'inflationary through 2035' timeline is empirically wrong for international markets—price compression is happening in 2026, not 2030+.
 
 ### Additional Evidence (extend)
-*Source: [[2026-03-21-semaglutide-us-import-wall-gray-market-pressure]] | Added: 2026-03-21*
+*Source: 2026-03-21-semaglutide-us-import-wall-gray-market-pressure | Added: 2026-03-21*
 
 US patent protection extends to 2031-2033 for Ozempic and Wegovy, creating a legal wall that prevents approved generic competition until then. The compounding pharmacy channel that provided affordable access during 2023-2025 closed in February 2025 when FDA removed semaglutide from the shortage list. This means the US will remain 'inflationary' through legal channels through 2031-2033, but gray market pressure from $15/month Indian generics versus $1,200/month Wegovy will create illegal importation at scale.
 
 ### Additional Evidence (challenge)
-*Source: [[2026-03-22-health-canada-rejects-dr-reddys-semaglutide]] | Added: 2026-03-22*
+*Source: 2026-03-22-health-canada-rejects-dr-reddys-semaglutide | Added: 2026-03-22*
 
 Health Canada rejected Dr. Reddy's generic semaglutide application in October 2025, delaying Canada launch to 2027 at earliest (8-12 month review cycle after resubmission). This contradicts the Session 9 projection of May 2026 Canada launch and reveals regulatory friction as a significant barrier to generic GLP-1 market entry. Canada's patents expired January 2026, but regulatory approval does not automatically follow patent expiration. The delay removes the primary high-income market data point for 2026, leaving only India's $15-55/month pricing as the sole confirmed generic market reference. Canada was expected to establish pricing floors for high-income markets with US-comparable health infrastructure, but that calibration point is now delayed 12+ months beyond patent cliff.
 

domains/health/clinical-ai-chatbot-misuse-documented-as-top-patient-safety-hazard-two-consecutive-years.md

@@ -11,9 +11,9 @@ scope: causal
 sourcer: ECRI
 related_claims: ["[[human-in-the-loop clinical AI degrades to worse-than-AI-alone because physicians both de-skill from reliance and introduce errors when overriding correct outputs]]", "[[medical LLM benchmark performance does not translate to clinical impact because physicians with and without AI access achieve similar diagnostic accuracy in randomized trials]]", "[[healthcare AI regulation needs blank-sheet redesign because the FDA drug-and-device model built for static products cannot govern continuously learning software]]"]
 supports:
-  - "Clinical AI deregulation is occurring during active harm accumulation not after evidence of safety as demonstrated by simultaneous FDA enforcement discretion expansion and ECRI top hazard designation in January 2026"
+- Clinical AI deregulation is occurring during active harm accumulation not after evidence of safety as demonstrated by simultaneous FDA enforcement discretion expansion and ECRI top hazard designation in January 2026
 reweave_edges:
-  - "Clinical AI deregulation is occurring during active harm accumulation not after evidence of safety as demonstrated by simultaneous FDA enforcement discretion expansion and ECRI top hazard designation in January 2026|supports|2026-04-04"
+- Clinical AI deregulation is occurring during active harm accumulation not after evidence of safety as demonstrated by simultaneous FDA enforcement discretion expansion and ECRI top hazard designation in January 2026|supports|2026-04-04
 ---
 
 # Clinical AI chatbot misuse is a documented ongoing harm source not a theoretical risk as evidenced by ECRI ranking it the number one health technology hazard for two consecutive years

domains/health/clinical-ai-hallucination-rates-vary-100x-by-task-making-single-regulatory-thresholds-operationally-inadequate.md

@@ -11,9 +11,9 @@ scope: structural
 sourcer: npj Digital Medicine
 related_claims: ["[[AI scribes reached 92 percent provider adoption in under 3 years because documentation is the rare healthcare workflow where AI value is immediate unambiguous and low-risk]]", "[[healthcare AI regulation needs blank-sheet redesign because the FDA drug-and-device model built for static products cannot govern continuously learning software]]"]
 supports:
-  - "No regulatory body globally has established mandatory hallucination rate benchmarks for clinical AI despite evidence base and proposed frameworks"
+- No regulatory body globally has established mandatory hallucination rate benchmarks for clinical AI despite evidence base and proposed frameworks
 reweave_edges:
-  - "No regulatory body globally has established mandatory hallucination rate benchmarks for clinical AI despite evidence base and proposed frameworks|supports|2026-04-04"
+- No regulatory body globally has established mandatory hallucination rate benchmarks for clinical AI despite evidence base and proposed frameworks|supports|2026-04-04
 ---
 
 # Clinical AI hallucination rates vary 100x by task making single regulatory thresholds operationally inadequate

domains/health/fda-2026-cds-enforcement-discretion-expands-to-single-recommendation-ai-without-defining-clinical-appropriateness.md

@@ -11,11 +11,11 @@ scope: structural
 sourcer: "Covington & Burling LLP"
 related_claims: ["[[healthcare AI regulation needs blank-sheet redesign because the FDA drug-and-device model built for static products cannot govern continuously learning software]]", "[[human-in-the-loop clinical AI degrades to worse-than-AI-alone because physicians both de-skill from reliance and introduce errors when overriding correct outputs]]"]
 related:
-  - "FDA's 2026 CDS guidance treats automation bias as a transparency problem solvable by showing clinicians the underlying logic despite research evidence that physicians defer to AI outputs even when reasoning is visible and reviewable"
+- FDA's 2026 CDS guidance treats automation bias as a transparency problem solvable by showing clinicians the underlying logic despite research evidence that physicians defer to AI outputs even when reasoning is visible and reviewable
-  - "Clinical AI deregulation is occurring during active harm accumulation not after evidence of safety as demonstrated by simultaneous FDA enforcement discretion expansion and ECRI top hazard designation in January 2026"
+- Clinical AI deregulation is occurring during active harm accumulation not after evidence of safety as demonstrated by simultaneous FDA enforcement discretion expansion and ECRI top hazard designation in January 2026
 reweave_edges:
-  - "FDA's 2026 CDS guidance treats automation bias as a transparency problem solvable by showing clinicians the underlying logic despite research evidence that physicians defer to AI outputs even when reasoning is visible and reviewable|related|2026-04-03"
+- FDA's 2026 CDS guidance treats automation bias as a transparency problem solvable by showing clinicians the underlying logic despite research evidence that physicians defer to AI outputs even when reasoning is visible and reviewable|related|2026-04-03
-  - "Clinical AI deregulation is occurring during active harm accumulation not after evidence of safety as demonstrated by simultaneous FDA enforcement discretion expansion and ECRI top hazard designation in January 2026|related|2026-04-04"
+- Clinical AI deregulation is occurring during active harm accumulation not after evidence of safety as demonstrated by simultaneous FDA enforcement discretion expansion and ECRI top hazard designation in January 2026|related|2026-04-04
 ---
 
 # FDA's 2026 CDS guidance expands enforcement discretion to cover AI tools providing single clinically appropriate recommendations while leaving clinical appropriateness undefined and requiring no bias evaluation or post-market surveillance

domains/health/generative-ai-medical-devices-require-new-regulatory-frameworks-because-non-determinism-continuous-updates-and-inherent-hallucination-are-architectural-properties.md

@@ -11,9 +11,9 @@ scope: structural
 sourcer: npj Digital Medicine authors
 related_claims: ["[[healthcare AI regulation needs blank-sheet redesign because the FDA drug-and-device model built for static products cannot govern continuously learning software]]", "[[OpenEvidence became the fastest-adopted clinical technology in history reaching 40 percent of US physicians daily within two years]]", "[[ambient AI documentation reduces physician documentation burden by 73 percent but the relationship between automation and burnout is more complex than time savings alone]]"]
 supports:
-  - "No regulatory body globally has established mandatory hallucination rate benchmarks for clinical AI despite evidence base and proposed frameworks"
+- No regulatory body globally has established mandatory hallucination rate benchmarks for clinical AI despite evidence base and proposed frameworks
 reweave_edges:
-  - "No regulatory body globally has established mandatory hallucination rate benchmarks for clinical AI despite evidence base and proposed frameworks|supports|2026-04-04"
+- No regulatory body globally has established mandatory hallucination rate benchmarks for clinical AI despite evidence base and proposed frameworks|supports|2026-04-04
 ---
 
 # Generative AI in medical devices requires categorically different regulatory frameworks than narrow AI because non-deterministic outputs, continuous model updates, and inherent hallucination are architectural properties not correctable defects

domains/health/glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints.md

@@ -6,14 +6,14 @@ confidence: likely
 source: "NEJM FLOW Trial kidney outcomes, Nature Medicine SGLT2 combination analysis"
 created: 2026-03-11
 related:
-  - "GLP-1 receptor agonists show 20% individual-level mortality reduction but are projected to reduce US population mortality by only 3.5% by 2045 because access barriers and adherence constraints create a 20-year lag between clinical efficacy and population-level detectability"
+- GLP-1 receptor agonists show 20% individual-level mortality reduction but are projected to reduce US population mortality by only 3.5% by 2045 because access barriers and adherence constraints create a 20-year lag between clinical efficacy and population-level detectability
-  - "semaglutide cardiovascular benefit is 67 percent independent of weight loss with inflammation as primary mediator"
+- semaglutide cardiovascular benefit is 67 percent independent of weight loss with inflammation as primary mediator
 reweave_edges:
-  - "GLP-1 receptor agonists show 20% individual-level mortality reduction but are projected to reduce US population mortality by only 3.5% by 2045 because access barriers and adherence constraints create a 20-year lag between clinical efficacy and population-level detectability|related|2026-04-04"
+- GLP-1 receptor agonists show 20% individual-level mortality reduction but are projected to reduce US population mortality by only 3.5% by 2045 because access barriers and adherence constraints create a 20-year lag between clinical efficacy and population-level detectability|related|2026-04-04
-  - "semaglutide cardiovascular benefit is 67 percent independent of weight loss with inflammation as primary mediator|related|2026-04-04"
+- semaglutide cardiovascular benefit is 67 percent independent of weight loss with inflammation as primary mediator|related|2026-04-04
-  - "semaglutide reduces kidney disease progression 24 percent and delays dialysis creating largest per patient cost savings|supports|2026-04-04"
+- semaglutide reduces kidney disease progression 24 percent and delays dialysis creating largest per patient cost savings|supports|2026-04-04
 supports:
-  - "semaglutide reduces kidney disease progression 24 percent and delays dialysis creating largest per patient cost savings"
+- semaglutide reduces kidney disease progression 24 percent and delays dialysis creating largest per patient cost savings
 ---
 
 # GLP-1 multi-organ protection creates compounding value across kidney cardiovascular and metabolic endpoints simultaneously rather than treating conditions in isolation
@@ -71,13 +71,13 @@ Medicare modeling quantifies the compound value: 38,950 CV events avoided, 6,180
 
 
 ### Additional Evidence (extend)
-*Source: [[2026-01-13-aon-glp1-employer-cost-savings-cancer-reduction]] | Added: 2026-03-18*
+*Source: 2026-01-13-aon-glp1-employer-cost-savings-cancer-reduction | Added: 2026-03-18*
 
 Aon's 192K patient study found adherent GLP-1 users (80%+) had 47% fewer MACE hospitalizations for women and 26% for men, with the sex differential suggesting larger cardiovascular benefits for women than previously documented.
 
 
 ### Additional Evidence (extend)
-*Source: [[2026-01-13-aon-glp1-employer-cost-savings-cancer-reduction]] | Added: 2026-03-19*
+*Source: 2026-01-13-aon-glp1-employer-cost-savings-cancer-reduction | Added: 2026-03-19*
 
 Aon's 192,000+ patient analysis adds cancer risk reduction to the multi-organ benefit profile: female GLP-1 users showed ~50% lower ovarian cancer incidence and 14% lower breast cancer incidence. Also associated with lower rates of osteoporosis, rheumatoid arthritis, and fewer hospitalizations for alcohol/drug abuse and bariatric surgery. The sex-differential in MACE reduction (47% for women vs 26% for men) suggests benefits may be larger for women, which has implications for risk adjustment in Medicare Advantage.
 

domains/health/glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md

@@ -5,11 +5,12 @@ description: "Two-year real-world data shows only 15% of non-diabetic obesity pa
 confidence: likely
 source: "Journal of Managed Care & Specialty Pharmacy, Real-world Persistence and Adherence to GLP-1 RAs Among Obese Commercially Insured Adults Without Diabetes, 2024-08-01"
 created: 2026-03-11
-depends_on: ["GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035"]
+depends_on:
+- GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035
 challenges:
-  - "GLP-1 receptor agonists show 20% individual-level mortality reduction but are projected to reduce US population mortality by only 3.5% by 2045 because access barriers and adherence constraints create a 20-year lag between clinical efficacy and population-level detectability"
+- GLP-1 receptor agonists show 20% individual-level mortality reduction but are projected to reduce US population mortality by only 3.5% by 2045 because access barriers and adherence constraints create a 20-year lag between clinical efficacy and population-level detectability
 reweave_edges:
-  - "GLP-1 receptor agonists show 20% individual-level mortality reduction but are projected to reduce US population mortality by only 3.5% by 2045 because access barriers and adherence constraints create a 20-year lag between clinical efficacy and population-level detectability|challenges|2026-04-04"
+- GLP-1 receptor agonists show 20% individual-level mortality reduction but are projected to reduce US population mortality by only 3.5% by 2045 because access barriers and adherence constraints create a 20-year lag between clinical efficacy and population-level detectability|challenges|2026-04-04
 ---
 
 # GLP-1 persistence drops to 15 percent at two years for non-diabetic obesity patients undermining chronic use economics
@@ -119,7 +120,7 @@ Aon data shows benefits scale dramatically with adherence: for diabetes patients
 Novo Nordisk's response to India's generic launch reveals market expansion strategy: only 200,000 of 250 million obese Indians are currently on GLP-1s. The company is competing on 'market expansion over price war,' suggesting the primary barrier is access/awareness, not price sensitivity. This implies persistence challenges may be access-driven in international markets rather than purely adherence-driven.
 
 ### Additional Evidence (extend)
-*Source: [[2025-04-01-jmir-glp1-digital-engagement-outcomes-retrospective]] | Added: 2026-03-24*
+*Source: 2025-04-01-jmir-glp1-digital-engagement-outcomes-retrospective | Added: 2026-03-24*
 
 US real-world data from JMIR 2025 shows digital engagement produces 11.53% weight loss vs. 8% for non-engaged participants at month 5 (3.5pp advantage). Study covers both semaglutide and tirzepatide, demonstrating the behavioral support effect generalizes across GLP-1/GIP receptor agonists. When supply and coverage issues are addressed, persistence improves to 63%, suggesting the adherence gap is partially addressable through digital platform integration (live coaching, monitoring, education).
 

domains/health/glp-1-population-mortality-impact-delayed-20-years-by-access-and-adherence-constraints.md

@@ -11,9 +11,9 @@ scope: structural
 sourcer: RGA (Reinsurance Group of America)
 related_claims: ["[[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]]", "[[medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate as four independent methodologies confirm]]"]
 supports:
-  - "GLP-1 access structure is inverted relative to clinical need because populations with highest obesity prevalence and cardiometabolic risk face the highest barriers creating an equity paradox where the most effective cardiovascular intervention will disproportionately benefit already-advantaged populations"
+- GLP-1 access structure is inverted relative to clinical need because populations with highest obesity prevalence and cardiometabolic risk face the highest barriers creating an equity paradox where the most effective cardiovascular intervention will disproportionately benefit already-advantaged populations
 reweave_edges:
-  - "GLP-1 access structure is inverted relative to clinical need because populations with highest obesity prevalence and cardiometabolic risk face the highest barriers creating an equity paradox where the most effective cardiovascular intervention will disproportionately benefit already-advantaged populations|supports|2026-04-04"
+- GLP-1 access structure is inverted relative to clinical need because populations with highest obesity prevalence and cardiometabolic risk face the highest barriers creating an equity paradox where the most effective cardiovascular intervention will disproportionately benefit already-advantaged populations|supports|2026-04-04
 ---
 
 # GLP-1 receptor agonists show 20% individual-level mortality reduction but are projected to reduce US population mortality by only 3.5% by 2045 because access barriers and adherence constraints create a 20-year lag between clinical efficacy and population-level detectability

domains/health/hypertension-related-cvd-mortality-doubled-2000-2023-despite-available-treatment-indicating-behavioral-sdoh-failure.md

@@ -12,12 +12,12 @@ attribution:
     - handle: "jacc-data-report-authors"
       context: "JACC Data Report 2025, JACC Cardiovascular Statistics 2026, Hypertension journal 2000-2019 analysis"
 related:
-  - "racial disparities in hypertension persist after controlling for income and neighborhood indicating structural racism operates through unmeasured mechanisms"
+- racial disparities in hypertension persist after controlling for income and neighborhood indicating structural racism operates through unmeasured mechanisms
 reweave_edges:
-  - "racial disparities in hypertension persist after controlling for income and neighborhood indicating structural racism operates through unmeasured mechanisms|related|2026-04-03"
+- racial disparities in hypertension persist after controlling for income and neighborhood indicating structural racism operates through unmeasured mechanisms|related|2026-04-03
-  - "us cvd mortality bifurcating ischemic declining heart failure hypertension worsening|supports|2026-04-04"
+- us cvd mortality bifurcating ischemic declining heart failure hypertension worsening|supports|2026-04-04
 supports:
-  - "us cvd mortality bifurcating ischemic declining heart failure hypertension worsening"
+- us cvd mortality bifurcating ischemic declining heart failure hypertension worsening
 ---
 
 # Hypertension-related cardiovascular mortality nearly doubled in the United States 2000–2023 despite the availability of effective affordable generic antihypertensives indicating that hypertension management failure is a behavioral and social determinants problem not a pharmacological availability problem
@@ -33,12 +33,12 @@ This provides the strongest single empirical case for the claim that medical car
 ---
 
 ### Additional Evidence (extend)
-*Source: [[2024-xx-ajpm-cvd-mortality-trends-2010-2022-update-final-data]] | Added: 2026-03-31*
+*Source: 2024-xx-ajpm-cvd-mortality-trends-2010-2022-update-final-data | Added: 2026-03-31*
 
 US CVD age-adjusted mortality rate in 2022 returned to 2012 levels (434.6 per 100,000 for adults ≥35), erasing a decade of progress. Adults aged 35-54 experienced elimination of the preceding decade's CVD gains from 2019-2022, with 228,524 excess CVD deaths 2020-2022 (9% above expected). The midlife pattern is inconsistent with COVID harvesting (which primarily affects the frail elderly) and suggests structural disease load.
 
 ### Additional Evidence (extend)
-*Source: [[2024-06-xx-aha-hypertension-sdoh-systematic-review-57-studies]] | Added: 2026-03-31*
+*Source: 2024-06-xx-aha-hypertension-sdoh-systematic-review-57-studies | Added: 2026-03-31*
 
 Systematic review of 57 studies identifies the specific SDOH mechanisms: food insecurity, unemployment, poverty-level income, low education, and inadequate insurance independently predict hypertension prevalence and poor BP control. The review explicitly states that 'multilevel collaboration and community-engaged practices are necessary to reduce hypertension disparities — siloed clinical or technology interventions are insufficient.'
 

domains/health/hypertensive-disease-mortality-doubled-1999-2023-becoming-leading-contributing-cvd-cause.md

@@ -11,9 +11,9 @@ scope: causal
 sourcer: Yan et al. / JACC
 related_claims: ["[[Big Food companies engineer addictive products by hacking evolutionary reward pathways creating a noncommunicable disease epidemic more deadly than the famines specialization eliminated]]", "[[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]]"]
 supports:
-  - "us cvd mortality bifurcating ischemic declining heart failure hypertension worsening"
+- us cvd mortality bifurcating ischemic declining heart failure hypertension worsening
 reweave_edges:
-  - "us cvd mortality bifurcating ischemic declining heart failure hypertension worsening|supports|2026-04-04"
+- us cvd mortality bifurcating ischemic declining heart failure hypertension worsening|supports|2026-04-04
 ---
 
 # Hypertensive disease mortality doubled in the US from 1999 to 2023, becoming the leading contributing cause of cardiovascular death by 2022 because obesity and sedentary behavior create treatment-resistant metabolic burden
@@ -21,7 +21,6 @@ reweave_edges:
 The JACC Data Report shows hypertensive disease age-adjusted mortality rate (AAMR) doubled from 15.8 per 100,000 (1999) to 31.9 (2023), making it 'the fastest rising underlying cause of cardiovascular death.' Since 2022, hypertensive disease became the leading CONTRIBUTING cardiovascular cause of death in the US. The mechanism is structural: obesity prevalence, sedentary behavior, and metabolic syndrome create a treatment-resistant hypertension burden that pharmacological interventions (ACE inhibitors, ARBs, diuretics) can manage but not eliminate. The geographic and demographic pattern confirms this: increases are disproportionate in Southern states (higher baseline obesity, lower healthcare access), Black Americans (structural hypertension treatment gap), and rural vs. urban areas. This represents a fundamental divergence from ischemic heart disease, which declined over the same period due to acute care improvements (stenting, statins). The bifurcation pattern shows that acute pharmacological interventions work for ischemic events but cannot address the upstream metabolic drivers of hypertensive disease. The doubling occurred despite widespread availability of effective antihypertensive medications, indicating the problem is behavioral and structural, not pharmaceutical.
 
 ### Additional Evidence (confirm)
-*Source: [[2026-01-21-aha-2026-heart-disease-stroke-statistics-update]] | Added: 2026-04-03*
+*Source: 2026-01-21-aha-2026-heart-disease-stroke-statistics-update | Added: 2026-04-03*
 
 AHA 2026 statistics confirm hypertensive disease mortality doubled from 15.8 to 31.9 per 100,000 (1999-2023) and became the #1 contributing cardiovascular cause of death since 2022, surpassing ischemic heart disease. This is the definitive annual data source confirming the trend.
-

domains/health/lower-income-patients-show-higher-glp-1-discontinuation-rates-suggesting-affordability-not-just-clinical-factors-drive-persistence.md

@@ -6,18 +6,18 @@ confidence: experimental
 source: "Journal of Managed Care & Specialty Pharmacy, Real-world Persistence and Adherence to GLP-1 RAs Among Obese Commercially Insured Adults Without Diabetes, 2024-08-01"
 created: 2026-03-11
 related:
-  - "federal budget scoring methodology systematically undervalues preventive interventions because 10 year window excludes long term savings"
+- federal budget scoring methodology systematically undervalues preventive interventions because 10 year window excludes long term savings
-  - "glp 1 multi organ protection creates compounding value across kidney cardiovascular and metabolic endpoints"
+- glp 1 multi organ protection creates compounding value across kidney cardiovascular and metabolic endpoints
-  - "pcsk9 inhibitors achieved only 1 to 2 5 percent penetration despite proven efficacy demonstrating access mediated pharmacological ceiling"
+- pcsk9 inhibitors achieved only 1 to 2 5 percent penetration despite proven efficacy demonstrating access mediated pharmacological ceiling
-  - "GLP 1 cost evidence accelerates value based care adoption by proving that prevention first interventions generate net savings under capitation within 24 months"
+- GLP 1 cost evidence accelerates value based care adoption by proving that prevention first interventions generate net savings under capitation within 24 months
 reweave_edges:
-  - "federal budget scoring methodology systematically undervalues preventive interventions because 10 year window excludes long term savings|related|2026-03-31"
+- federal budget scoring methodology systematically undervalues preventive interventions because 10 year window excludes long term savings|related|2026-03-31
-  - "glp 1 multi organ protection creates compounding value across kidney cardiovascular and metabolic endpoints|related|2026-03-31"
+- glp 1 multi organ protection creates compounding value across kidney cardiovascular and metabolic endpoints|related|2026-03-31
-  - "pcsk9 inhibitors achieved only 1 to 2 5 percent penetration despite proven efficacy demonstrating access mediated pharmacological ceiling|related|2026-03-31"
+- pcsk9 inhibitors achieved only 1 to 2 5 percent penetration despite proven efficacy demonstrating access mediated pharmacological ceiling|related|2026-03-31
-  - "GLP 1 cost evidence accelerates value based care adoption by proving that prevention first interventions generate net savings under capitation within 24 months|related|2026-04-04"
+- GLP 1 cost evidence accelerates value based care adoption by proving that prevention first interventions generate net savings under capitation within 24 months|related|2026-04-04
-  - "GLP-1 access structure is inverted relative to clinical need because populations with highest obesity prevalence and cardiometabolic risk face the highest barriers creating an equity paradox where the most effective cardiovascular intervention will disproportionately benefit already-advantaged populations|supports|2026-04-04"
+- GLP-1 access structure is inverted relative to clinical need because populations with highest obesity prevalence and cardiometabolic risk face the highest barriers creating an equity paradox where the most effective cardiovascular intervention will disproportionately benefit already-advantaged populations|supports|2026-04-04
 supports:
-  - "GLP-1 access structure is inverted relative to clinical need because populations with highest obesity prevalence and cardiometabolic risk face the highest barriers creating an equity paradox where the most effective cardiovascular intervention will disproportionately benefit already-advantaged populations"
+- GLP-1 access structure is inverted relative to clinical need because populations with highest obesity prevalence and cardiometabolic risk face the highest barriers creating an equity paradox where the most effective cardiovascular intervention will disproportionately benefit already-advantaged populations
 ---
 
 # Lower-income patients show higher GLP-1 discontinuation rates suggesting affordability not just clinical factors drive persistence
@@ -71,7 +71,7 @@ OBBBA work requirements threaten to remove ~10M from Medicaid coverage precisely
 ---
 
 ### Additional Evidence (extend)
-*Source: [[2026-03-29-circulation-cvqo-pcsk9-utilization-2015-2021]] | Added: 2026-03-29*
+*Source: 2026-03-29-circulation-cvqo-pcsk9-utilization-2015-2021 | Added: 2026-03-29*
 
 PCSK9 inhibitors show sociodemographic disparities in utilization independent of clinical indication. JAHA 2021 adoption study found Black and Hispanic ASCVD patients had lower PCSK9 utilization than white patients at all income levels. This pattern parallels GLP-1 discontinuation disparities, suggesting affordability/access barriers create systematic underutilization in lower-income and minority populations across multiple high-cost cardiovascular/metabolic drug classes.
 

domains/health/medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate as four independent methodologies confirm.md

@@ -6,12 +6,12 @@ created: 2026-02-20
 source: "Braveman & Egerter 2019, Schroeder 2007, County Health Rankings, Dever 1976"
 confidence: proven
 supports:
-  - "hypertension related cvd mortality doubled 2000 2023 despite available treatment indicating behavioral sdoh failure"
+- hypertension related cvd mortality doubled 2000 2023 despite available treatment indicating behavioral sdoh failure
 reweave_edges:
-  - "hypertension related cvd mortality doubled 2000 2023 despite available treatment indicating behavioral sdoh failure|supports|2026-03-31"
+- hypertension related cvd mortality doubled 2000 2023 despite available treatment indicating behavioral sdoh failure|supports|2026-03-31
-  - "us healthcare ranks last among peer nations despite highest spending because access and equity failures override clinical quality|related|2026-04-04"
+- us healthcare ranks last among peer nations despite highest spending because access and equity failures override clinical quality|related|2026-04-04
 related:
-  - "us healthcare ranks last among peer nations despite highest spending because access and equity failures override clinical quality"
+- us healthcare ranks last among peer nations despite highest spending because access and equity failures override clinical quality
 ---
 
 # medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate as four independent methodologies confirm
@@ -80,7 +80,7 @@ Amodei's complementary factors framework explicitly identifies 'human constraint
 PNAS 2026 attributes US life expectancy stagnation to 'a complex convergence of rising chronic disease, shifting behavioral risks, and increases in certain cancers among younger adults' — explicitly identifying behavioral and social factors as the drivers of cohort-level mortality deterioration, not medical care quality.
 
 ### Additional Evidence (confirm)
-*Source: [[2026-03-30-jacc-cvd-mortality-trends-1999-2023]] | Added: 2026-03-30*
+*Source: 2026-03-30-jacc-cvd-mortality-trends-1999-2023 | Added: 2026-03-30*
 
 Hypertension-related CVD mortality doubled 2000-2023 (23→43 per 100,000) despite widespread availability of effective, cheap generic antihypertensives. This is the strongest single empirical case for the 80-90% non-clinical determinants thesis because the failure occurs despite pharmacological solutions being universally accessible, proving the constraint is behavioral/SDOH not medical.
 

domains/health/nhs-demonstrates-universal-coverage-without-adequate-funding-produces-excellent-primary-care-but-catastrophic-specialty-access.md

@@ -6,11 +6,11 @@ confidence: likely
 source: "UK Parliament Public Accounts Committee, BMA, NHS England (2024-2025)"
 created: 2025-01-15
 supports:
-  - "gatekeeping systems optimize primary care at the expense of specialty access creating structural bottlenecks"
+- gatekeeping systems optimize primary care at the expense of specialty access creating structural bottlenecks
-  - "us healthcare ranks last among peer nations despite highest spending because access and equity failures override clinical quality"
+- us healthcare ranks last among peer nations despite highest spending because access and equity failures override clinical quality
 reweave_edges:
-  - "gatekeeping systems optimize primary care at the expense of specialty access creating structural bottlenecks|supports|2026-03-31"
+- gatekeeping systems optimize primary care at the expense of specialty access creating structural bottlenecks|supports|2026-03-31
-  - "us healthcare ranks last among peer nations despite highest spending because access and equity failures override clinical quality|supports|2026-04-04"
+- us healthcare ranks last among peer nations despite highest spending because access and equity failures override clinical quality|supports|2026-04-04
 ---
 
 # NHS demonstrates universal coverage without adequate funding produces excellent primary care but catastrophic specialty access

domains/health/no-regulatory-body-globally-has-established-mandatory-hallucination-rate-benchmarks-for-clinical-ai-despite-evidence-base.md

@@ -11,11 +11,11 @@ scope: structural
 sourcer: npj Digital Medicine
 related_claims: ["[[AI scribes reached 92 percent provider adoption in under 3 years because documentation is the rare healthcare workflow where AI value is immediate unambiguous and low-risk]]", "[[healthcare AI regulation needs blank-sheet redesign because the FDA drug-and-device model built for static products cannot govern continuously learning software]]"]
 supports:
-  - "Clinical AI hallucination rates vary 100x by task making single regulatory thresholds operationally inadequate"
+- Clinical AI hallucination rates vary 100x by task making single regulatory thresholds operationally inadequate
-  - "Generative AI in medical devices requires categorically different regulatory frameworks than narrow AI because non-deterministic outputs, continuous model updates, and inherent hallucination are architectural properties not correctable defects"
+- Generative AI in medical devices requires categorically different regulatory frameworks than narrow AI because non-deterministic outputs, continuous model updates, and inherent hallucination are architectural properties not correctable defects
 reweave_edges:
-  - "Clinical AI hallucination rates vary 100x by task making single regulatory thresholds operationally inadequate|supports|2026-04-04"
+- Clinical AI hallucination rates vary 100x by task making single regulatory thresholds operationally inadequate|supports|2026-04-04
-  - "Generative AI in medical devices requires categorically different regulatory frameworks than narrow AI because non-deterministic outputs, continuous model updates, and inherent hallucination are architectural properties not correctable defects|supports|2026-04-04"
+- Generative AI in medical devices requires categorically different regulatory frameworks than narrow AI because non-deterministic outputs, continuous model updates, and inherent hallucination are architectural properties not correctable defects|supports|2026-04-04
 ---
 
 # No regulatory body globally has established mandatory hallucination rate benchmarks for clinical AI despite evidence base and proposed frameworks

domains/health/semaglutide-achieves-47-percent-one-year-persistence-versus-19-percent-for-liraglutide-showing-drug-specific-adherence-variation-of-2-5x.md

@@ -6,9 +6,9 @@ confidence: likely
 source: "Journal of Managed Care & Specialty Pharmacy, Real-world Persistence and Adherence to GLP-1 RAs Among Obese Commercially Insured Adults Without Diabetes, 2024-08-01"
 created: 2026-03-11
 related:
-  - "semaglutide reduces kidney disease progression 24 percent and delays dialysis creating largest per patient cost savings"
+- semaglutide reduces kidney disease progression 24 percent and delays dialysis creating largest per patient cost savings
 reweave_edges:
-  - "semaglutide reduces kidney disease progression 24 percent and delays dialysis creating largest per patient cost savings|related|2026-04-04"
+- semaglutide reduces kidney disease progression 24 percent and delays dialysis creating largest per patient cost savings|related|2026-04-04
 ---
 
 # Semaglutide achieves 47 percent one-year persistence versus 19 percent for liraglutide showing drug-specific adherence variation of 2.5x

domains/health/semaglutide-reduces-kidney-disease-progression-24-percent-and-delays-dialysis-creating-largest-per-patient-cost-savings.md

@@ -6,12 +6,12 @@ confidence: proven
 source: "NEJM FLOW Trial (N=3,533, stopped early for efficacy), FDA indication expansion 2024"
 created: 2026-03-11
 supports:
-  - "glp 1 multi organ protection creates compounding value across kidney cardiovascular and metabolic endpoints"
+- glp 1 multi organ protection creates compounding value across kidney cardiovascular and metabolic endpoints
 reweave_edges:
-  - "glp 1 multi organ protection creates compounding value across kidney cardiovascular and metabolic endpoints|supports|2026-03-31"
+- glp 1 multi organ protection creates compounding value across kidney cardiovascular and metabolic endpoints|supports|2026-03-31
-  - "semaglutide achieves 47 percent one year persistence versus 19 percent for liraglutide showing drug specific adherence variation of 2 5x|related|2026-04-04"
+- semaglutide achieves 47 percent one year persistence versus 19 percent for liraglutide showing drug specific adherence variation of 2 5x|related|2026-04-04
 related:
-  - "semaglutide achieves 47 percent one year persistence versus 19 percent for liraglutide showing drug specific adherence variation of 2 5x"
+- semaglutide achieves 47 percent one year persistence versus 19 percent for liraglutide showing drug specific adherence variation of 2 5x
 ---
 
 # Semaglutide reduces kidney disease progression by 24 percent and delays dialysis onset creating the largest per-patient cost savings of any GLP-1 indication because dialysis costs $90K+ per year
@@ -49,7 +49,7 @@ SELECT trial economic model shows $2,074 per-subject lifetime savings from avoid
 
 
 ### Additional Evidence (extend)
-*Source: [[2025-06-01-value-in-health-comprehensive-semaglutide-medicare-economics]] | Added: 2026-03-18*
+*Source: 2025-06-01-value-in-health-comprehensive-semaglutide-medicare-economics | Added: 2026-03-18*
 
 In the Medicare comprehensive model, CKD-related savings contribute $2,074 per subject treated, which is smaller than T2D savings ($14,431/subject) but still material. The 10-year modeling window may underestimate dialysis delay value since ESRD costs accumulate over longer periods. MASH savings were only $28M system-wide, suggesting treatment costs don't accumulate enough in the 10-year window to produce large offsets despite clinical efficacy.
 

domains/health/the FDA now separates wellness devices from medical devices based on claims not sensor technology enabling health insights without full medical device classification.md

@@ -6,9 +6,9 @@ created: 2026-02-17
 source: "FDA January 2026 guidance update on CDS and general wellness; TEMPO pilot (Federal Register December 2025); Faegre Drinker analysis"
 confidence: likely
 related:
-  - "tempo pilot creates medicare digital health pathway while medicaid coverage contracts"
+- tempo pilot creates medicare digital health pathway while medicaid coverage contracts
 reweave_edges:
-  - "tempo pilot creates medicare digital health pathway while medicaid coverage contracts|related|2026-04-04"
+- tempo pilot creates medicare digital health pathway while medicaid coverage contracts|related|2026-04-04
 ---
 
 # the FDA now separates wellness devices from medical devices based on claims not sensor technology enabling health insights without full medical device classification
@@ -22,7 +22,7 @@ This two-track system has structural implications. It lowers the barrier for get
 ---
 
 ### Additional Evidence (extend)
-*Source: [[2025-12-05-fda-tempo-pilot-cms-access-digital-health-ckm]] | Added: 2026-03-31*
+*Source: 2025-12-05-fda-tempo-pilot-cms-access-digital-health-ckm | Added: 2026-03-31*
 
 TEMPO pilot creates the next layer of FDA digital health deregulation beyond the January 2026 CDS guidance: enforcement discretion for uncleared devices deployed in real-world Medicare settings. This is a structured pathway for collecting the outcomes data that traditional FDA review requires, creating a workaround for the regulatory pathway problem where companies need data to get clearance but need clearance to collect data at scale.
 

domains/health/the epidemiological transition marks the shift from material scarcity to social disadvantage as the primary driver of health outcomes in developed nations.md

@@ -6,9 +6,9 @@ source: "Architectural Investing, Ch. Epidemiological Transition; Wilkinson (199
 confidence: likely
 created: 2026-02-28
 related:
-  - "us healthcare ranks last among peer nations despite highest spending because access and equity failures override clinical quality"
+- us healthcare ranks last among peer nations despite highest spending because access and equity failures override clinical quality
 reweave_edges:
-  - "us healthcare ranks last among peer nations despite highest spending because access and equity failures override clinical quality|related|2026-04-04"
+- us healthcare ranks last among peer nations despite highest spending because access and equity failures override clinical quality|related|2026-04-04
 ---
 
 # the epidemiological transition marks the shift from material scarcity to social disadvantage as the primary driver of health outcomes in developed nations
@@ -31,13 +31,13 @@ Since specialization and value form an autocatalytic feedback loop where each am
 
 
 ### Additional Evidence (confirm)
-*Source: [[2024-09-19-commonwealth-fund-mirror-mirror-2024]] | Added: 2026-03-12 | Extractor: anthropic/claude-sonnet-4.5*
+*Source: 2024-09-19-commonwealth-fund-mirror-mirror-2024 | Added: 2026-03-12 | Extractor: anthropic/claude-sonnet-4.5*
 
 The Commonwealth Fund's 2024 international comparison demonstrates this transition empirically across 10 developed nations. All countries compared (Australia, Canada, France, Germany, Netherlands, New Zealand, Sweden, Switzerland, UK, US) have eliminated material scarcity in healthcare — all possess advanced clinical capabilities and universal or near-universal access infrastructure. Yet health outcomes vary dramatically. The US spends >16% of GDP (highest by far) with worst outcomes, while top performers (Australia, Netherlands) spend the lowest percentage of GDP. The differentiator is not clinical capability (US ranks 2nd in care process quality) but access structures and equity — social determinants. This proves that among developed nations with sufficient material resources, social disadvantage (who gets care, discrimination, equity barriers) drives outcomes more powerfully than clinical quality or spending volume.
 
 
 ### Additional Evidence (extend)
-*Source: [[2025-06-01-cell-med-glp1-societal-implications-obesity]] | Added: 2026-03-15*
+*Source: 2025-06-01-cell-med-glp1-societal-implications-obesity | Added: 2026-03-15*
 
 GLP-1 access inequality demonstrates the epidemiological transition in action: the intervention addresses metabolic disease (post-transition health problem) but access stratifies by wealth and insurance status (social disadvantage), potentially widening health inequalities even as population-level outcomes improve. The WHO's emphasis on 'multisectoral action' and 'healthier environments' acknowledges that pharmaceutical solutions alone cannot address socially-determined health outcomes.
 

domains/health/us-heart-failure-mortality-reversed-1999-2023-exceeding-baseline-despite-acute-care-improvements.md

@@ -11,9 +11,9 @@ scope: causal
 sourcer: Yan et al. / JACC
 related_claims: ["[[Americas declining life expectancy is driven by deaths of despair concentrated in populations and regions most damaged by economic restructuring since the 1980s]]", "[[the epidemiological transition marks the shift from material scarcity to social disadvantage as the primary driver of health outcomes in developed nations]]"]
 supports:
-  - "us cvd mortality bifurcating ischemic declining heart failure hypertension worsening"
+- us cvd mortality bifurcating ischemic declining heart failure hypertension worsening
 reweave_edges:
-  - "us cvd mortality bifurcating ischemic declining heart failure hypertension worsening|supports|2026-04-04"
+- us cvd mortality bifurcating ischemic declining heart failure hypertension worsening|supports|2026-04-04
 ---
 
 # US heart failure mortality in 2023 exceeds its 1999 baseline after a 12-year reversal, demonstrating that improved acute ischemic care creates a larger pool of survivors with cardiometabolic disease burden
@@ -21,7 +21,6 @@ reweave_edges:
 The JACC Data Report analyzing CDC WONDER database shows heart failure age-adjusted mortality rate (AAMR) followed a U-shaped trajectory: declined from 20.3 per 100,000 (1999) to 16.9 (2011), then reversed entirely to reach 21.6 in 2023—exceeding the 1999 baseline. This represents a complete structural reversal over 12 years. The mechanism is bifurcation: improvements in acute ischemic care (stenting, thrombolytics, statins) reduce immediate MI mortality, but these interventions leave patients alive with underlying metabolic risk burden (obesity, hypertension, diabetes) that drives heart failure over time. Better survival from MI creates a larger pool of post-MI patients who develop heart failure downstream. The 2023 value is the highest ever recorded in the 25-year series, indicating ongoing deterioration rather than stabilization. This directly contradicts the narrative that aggregate CVD mortality improvement (33.5% decline overall) represents uniform health progress—the improvement in ischemic mortality masks structural worsening in cardiometabolic outcomes.
 
 ### Additional Evidence (confirm)
-*Source: [[2026-01-21-aha-2026-heart-disease-stroke-statistics-update]] | Added: 2026-04-03*
+*Source: 2026-01-21-aha-2026-heart-disease-stroke-statistics-update | Added: 2026-04-03*
 
 2023 data shows heart failure mortality at 21.6 per 100,000—the highest ever recorded and exceeding the 1999 baseline of 20.3. After declining to 16.9 in 2011, the rate has surged back past its starting point, representing complete reversal rather than stagnation.
-

domains/health/value-based care transitions stall at the payment boundary because 60 percent of payments touch value metrics but only 14 percent bear full risk.md

@@ -6,13 +6,13 @@ created: 2026-02-17
 source: "HCP-LAN 2022-2025 measurement; IMO Health VBC Update June 2025; Grand View Research VBC market analysis; Larsson et al NEJM Catalyst 2022"
 confidence: likely
 related:
-  - "federal budget scoring methodology systematically undervalues preventive interventions because 10 year window excludes long term savings"
+- federal budget scoring methodology systematically undervalues preventive interventions because 10 year window excludes long term savings
-  - "home based care could capture 265 billion in medicare spending by 2025 through hospital at home remote monitoring and post acute shift"
+- home based care could capture 265 billion in medicare spending by 2025 through hospital at home remote monitoring and post acute shift
-  - "GLP 1 cost evidence accelerates value based care adoption by proving that prevention first interventions generate net savings under capitation within 24 months"
+- GLP 1 cost evidence accelerates value based care adoption by proving that prevention first interventions generate net savings under capitation within 24 months
 reweave_edges:
-  - "federal budget scoring methodology systematically undervalues preventive interventions because 10 year window excludes long term savings|related|2026-03-31"
+- federal budget scoring methodology systematically undervalues preventive interventions because 10 year window excludes long term savings|related|2026-03-31
-  - "home based care could capture 265 billion in medicare spending by 2025 through hospital at home remote monitoring and post acute shift|related|2026-03-31"
+- home based care could capture 265 billion in medicare spending by 2025 through hospital at home remote monitoring and post acute shift|related|2026-03-31
-  - "GLP 1 cost evidence accelerates value based care adoption by proving that prevention first interventions generate net savings under capitation within 24 months|related|2026-04-04"
+- GLP 1 cost evidence accelerates value based care adoption by proving that prevention first interventions generate net savings under capitation within 24 months|related|2026-04-04
 ---
 
 # value-based care transitions stall at the payment boundary because 60 percent of payments touch value metrics but only 14 percent bear full risk
@@ -57,25 +57,25 @@ The BALANCE Model moves payment toward genuine risk by adjusting capitated rates
 
 
 ### Additional Evidence (extend)
-*Source: [[2026-02-01-cms-balance-model-details-rfa-design]] | Added: 2026-03-16*
+*Source: 2026-02-01-cms-balance-model-details-rfa-design | Added: 2026-03-16*
 
 CMS BALANCE Model demonstrates policy recognition of the VBC misalignment by implementing capitation adjustment (paying plans MORE for obesity coverage) plus reinsurance (removing tail risk) rather than expecting prevention incentives to emerge from capitation alone. This is explicit structural redesign around the identified barriers.
 
 
 ### Additional Evidence (extend)
-*Source: [[2025-01-01-nashp-chw-state-policies-2024-2025]] | Added: 2026-03-18*
+*Source: 2025-01-01-nashp-chw-state-policies-2024-2025 | Added: 2026-03-18*
 
 CHW reimbursement infrastructure demonstrates the same payment boundary stall in the SDOH domain: 20 states with approved SPAs after 17 years, with billing code uptake remaining slow even where reimbursement is technically available. The bottleneck is not policy approval but operational infrastructure — CBOs cannot contract with healthcare entities, transportation costs are not covered, and 'community care hubs' are emerging as coordination infrastructure. This parallels VBC's 60% touch / 14% risk gap: technical capability exists but the operational infrastructure to execute at scale does not.
 
 
 ### Additional Evidence (extend)
-*Source: [[2026-03-20-fierce-healthcare-obbba-domino-effect]] | Added: 2026-03-20*
+*Source: 2026-03-20-fierce-healthcare-obbba-domino-effect | Added: 2026-03-20*
 
 Fierce Healthcare's 2026 outlook shows the OBBBA domino mechanism: Medicaid work requirements → coverage loss → newly uninsured seek ER care → uncompensated care absorbed by health systems → financial stress → less investment in VBC infrastructure → VBC transition slows. This provides a specific causal pathway for how policy-induced coverage disruption directly undermines VBC adoption by forcing health systems to absorb uncompensated care costs that would otherwise fund infrastructure investment.
 
 
 ### Additional Evidence (extend)
-*Source: [[2026-03-20-obbba-vbc-enrollment-stability-mechanism]] | Added: 2026-03-20*
+*Source: 2026-03-20-obbba-vbc-enrollment-stability-mechanism | Added: 2026-03-20*
 
 VBC transitions face a second stall mechanism beyond the payment boundary: population stability. OBBBA's work requirements and semi-annual redeterminations fragment continuous enrollment, preventing VBC plans from capturing prevention investment payback even when payment models are correctly structured. CHW programs with 12-18 month payback periods fail when members churn before savings realize. This is a structural barrier independent of risk-bearing levels.
 

domains/space-development/Axiom Space has the strongest operational position for commercial orbital habitation but the weakest financial position among funded competitors.md

@@ -6,12 +6,12 @@ confidence: likely
 source: "Astra, Axiom Space research profile February 2026"
 created: 2026-02-17
 depends_on:
-  - "commercial space stations are the next infrastructure bet as ISS retirement creates a void that 4 companies are racing to fill by 2030"
+- commercial space stations are the next infrastructure bet as ISS retirement creates a void that 4 companies are racing to fill by 2030
-  - "the commercial space station transition from ISS creates a gap risk that could end 25 years of continuous human presence in low Earth orbit"
+- the commercial space station transition from ISS creates a gap risk that could end 25 years of continuous human presence in low Earth orbit
 related:
-  - "Vast is building the first commercial space station with Haven 1 launching 2027 funded by Jed McCaleb 1B personal commitment and targeting artificial gravity stations by the 2030s"
+- Vast is building the first commercial space station with Haven 1 launching 2027 funded by Jed McCaleb 1B personal commitment and targeting artificial gravity stations by the 2030s
 reweave_edges:
-  - "Vast is building the first commercial space station with Haven 1 launching 2027 funded by Jed McCaleb 1B personal commitment and targeting artificial gravity stations by the 2030s|related|2026-04-04"
+- Vast is building the first commercial space station with Haven 1 launching 2027 funded by Jed McCaleb 1B personal commitment and targeting artificial gravity stations by the 2030s|related|2026-04-04
 ---
 
 # Axiom Space has the strongest operational position for commercial orbital habitation but the weakest financial position among funded competitors
@@ -41,4 +41,4 @@ Relevant Notes:
 - [[the commercial space station transition from ISS creates a gap risk that could end 25 years of continuous human presence in low Earth orbit]] — Axiom's financial difficulties are the single largest risk factor for the gap scenario
 
 Topics:
-- [[space exploration and development]]
+- space exploration and development

domains/space-development/Blue Origin cislunar infrastructure strategy mirrors AWS by building comprehensive platform layers while competitors optimize individual services.md

@@ -5,11 +5,12 @@ description: "Bezos funds $14B+ to build launch, landers, stations, and comms co
 confidence: experimental
 source: "Astra, Blue Origin research profile February 2026"
 created: 2026-03-20
-challenged_by: ["historically slow execution and total Bezos dependency — two successful New Glenn flights is a start not a pattern"]
+challenged_by:
+- historically slow execution and total Bezos dependency — two successful New Glenn flights is a start not a pattern
 related:
-  - "Blue Origin's concurrent announcement of Project Sunrise (51,600 satellites) and New Glenn production ramp while NG-3 slips 6 weeks illustrates the gap between ambitious strategic vision and operational execution capability"
+- Blue Origin's concurrent announcement of Project Sunrise (51,600 satellites) and New Glenn production ramp while NG-3 slips 6 weeks illustrates the gap between ambitious strategic vision and operational execution capability
 reweave_edges:
-  - "Blue Origin's concurrent announcement of Project Sunrise (51,600 satellites) and New Glenn production ramp while NG-3 slips 6 weeks illustrates the gap between ambitious strategic vision and operational execution capability|related|2026-04-04"
+- Blue Origin's concurrent announcement of Project Sunrise (51,600 satellites) and New Glenn production ramp while NG-3 slips 6 weeks illustrates the gap between ambitious strategic vision and operational execution capability|related|2026-04-04
 ---
 
 # Blue Origin cislunar infrastructure strategy mirrors AWS by building comprehensive platform layers while competitors optimize individual services
@@ -29,7 +30,7 @@ The key risk is historically slow execution and total Bezos dependency. Two succ
 ---
 
 ### Additional Evidence (challenge)
-*Source: [[2026-03-28-nasaspaceflight-new-glenn-manufacturing-odc-ambitions]] | Added: 2026-03-28*
+*Source: 2026-03-28-nasaspaceflight-new-glenn-manufacturing-odc-ambitions | Added: 2026-03-28*
 
 Blue Origin's Project Sunrise ambitions (51,600 orbital data center satellites) require Starlink-like launch cadence, but actual New Glenn operations show 1.6 launches/year versus 12/year manufacturing capacity. The AWS-mirroring strategy assumes operational execution will scale with manufacturing, but 15 months of New Glenn operations reveal a 6-8x execution gap that makes the comprehensive platform buildout timeline implausible.
 

domains/space-development/SpaceX vertical integration across launch broadband and manufacturing creates compounding cost advantages that no competitor can replicate piecemeal.md

@@ -5,13 +5,14 @@ description: "SpaceX uses Starlink demand to drive launch cadence which drives r
 confidence: likely
 source: "Astra synthesis from SpaceX 2025 financials ($19B revenue, ~$2B net income), Starlink subscriber data (10M), launch cadence data (170 launches in 2025), Falcon 9 booster reuse records (32 flights on single first stage)"
 created: 2026-03-07
-challenged_by: "The flywheel thesis assumes Starlink revenue growth continues and that the broadband market sustains the cadence needed for reusability learning. Starlink faces regulatory barriers in several countries, spectrum allocation conflicts, and potential competition from non-LEO broadband (5G/6G terrestrial expansion). If Starlink growth plateaus, the flywheel loses its demand driver. Also, the xAI merger introduces execution complexity that could distract from launch operations."
+challenged_by:
+- The flywheel thesis assumes Starlink revenue growth continues and that the broadband market sustains the cadence needed for reusability learning. Starlink faces regulatory barriers in several countries, spectrum allocation conflicts, and potential competition from non-LEO broadband (5G/6G terrestrial expansion). If Starlink growth plateaus, the flywheel loses its demand driver. Also, the xAI merger introduces execution complexity that could distract from launch operations.
 related:
-  - "Blue Origin's concurrent announcement of Project Sunrise (51,600 satellites) and New Glenn production ramp while NG-3 slips 6 weeks illustrates the gap between ambitious strategic vision and operational execution capability"
+- Blue Origin's concurrent announcement of Project Sunrise (51,600 satellites) and New Glenn production ramp while NG-3 slips 6 weeks illustrates the gap between ambitious strategic vision and operational execution capability
-  - "varda vertical integration reduces space manufacturing access costs"
+- varda vertical integration reduces space manufacturing access costs
 reweave_edges:
-  - "Blue Origin's concurrent announcement of Project Sunrise (51,600 satellites) and New Glenn production ramp while NG-3 slips 6 weeks illustrates the gap between ambitious strategic vision and operational execution capability|related|2026-04-04"
+- Blue Origin's concurrent announcement of Project Sunrise (51,600 satellites) and New Glenn production ramp while NG-3 slips 6 weeks illustrates the gap between ambitious strategic vision and operational execution capability|related|2026-04-04
-  - "varda vertical integration reduces space manufacturing access costs|related|2026-04-04"
+- varda vertical integration reduces space manufacturing access costs|related|2026-04-04
 ---
 
 # SpaceX vertical integration across launch broadband and manufacturing creates compounding cost advantages that no competitor can replicate piecemeal
@@ -26,37 +27,37 @@ The question for the space industry is not whether SpaceX will be dominant but w
 
 
 ### Additional Evidence (challenge)
-*Source: [[2026-03-18-blue-origin-ng3-booster-reuse]] | Added: 2026-03-18*
+*Source: 2026-03-18-blue-origin-ng3-booster-reuse | Added: 2026-03-18*
 
 Blue Origin's patient capital model ($14B+ Bezos investment) produced a second operational reusable heavy-lift provider with successful booster landing on only 2nd orbital attempt (NG-2) and first reuse attempt at ~3 month turnaround (NG-3). The booster is designed for 25+ flights, approaching Falcon 9's operational reuse economics. This demonstrates that sustained capital investment without revenue pressure can produce competitive reusable launch capability, challenging the necessity of SpaceX's specific vertical integration model.
 
 
 ### Additional Evidence (extend)
-*Source: [[2026-03-18-varda-w5-vertically-integrated-bus]] | Added: 2026-03-18*
+*Source: 2026-03-18-varda-w5-vertically-integrated-bus | Added: 2026-03-18*
 
 Varda's vertical integration milestone (own bus + own heatshield) demonstrates the pattern extends beyond launch to space manufacturing. The C-PICA heatshield manufactured in-house at El Segundo enables faster iteration cycles and cost reduction through the same flywheel mechanism SpaceX uses for Falcon 9.
 
 
 ### Additional Evidence (challenge)
-*Source: [[2026-03-18-new-glenn-ng3-booster-reuse-pending]] | Added: 2026-03-18*
+*Source: 2026-03-18-new-glenn-ng3-booster-reuse-pending | Added: 2026-03-18*
 
 Blue Origin achieved booster landing on only their 2nd attempt (NG-2, Nov 2025) and is now demonstrating reuse on NG-3 with a 3-month turnaround. This suggests non-SpaceX players can achieve operational reuse cadence faster than SpaceX's historical learning curve, challenging the claim that SpaceX's advantages are unreplicable. However, the 3-month turnaround is still 3-6x slower than SpaceX's mature operations, so the competitive moat may be in optimization speed rather than capability access.
 
 
 ### Additional Evidence (extend)
-*Source: [[2026-03-00-commercial-stations-haven1-slip-orbital-reef-delays]] | Added: 2026-03-19*
+*Source: 2026-03-00-commercial-stations-haven1-slip-orbital-reef-delays | Added: 2026-03-19*
 
 Orbital Reef's multi-party structure (Blue Origin, Sierra Space, Boeing) appears to be creating coordination delays and funding allocation challenges, contrasting with vertically integrated approaches. Blue Origin's capital allocation across New Shepard, New Glenn, BE-4 engines, and Orbital Reef simultaneously may be straining even Bezos's 'patient capital' model—the first signal that Blue Origin's multi-program strategy faces resource constraints. This suggests vertical integration advantages extend beyond technical efficiency to capital allocation coherence.
 
 ---
 
 ### Additional Evidence (extend)
-*Source: [[2025-12-10-cnbc-starcloud-first-llm-trained-space-h100]] | Added: 2026-03-24*
+*Source: 2025-12-10-cnbc-starcloud-first-llm-trained-space-h100 | Added: 2026-03-24*
 
 Starcloud's use of SpaceX rideshare to bootstrap orbital AI compute, combined with NVIDIA's strategic backing (GPU manufacturer + compute operator relationship), suggests a similar vertical-integration pattern emerging in the orbital data center sector. NVIDIA's Space Computing initiative and commitment to deploy Blackwell platforms by October 2026 creates a semiconductor-platform-vendor-to-orbital-operator relationship analogous to SpaceX's launch-to-Starlink integration. This may indicate that vertical integration advantages compound across different space industry segments, not just within SpaceX's specific stack.
 
 ### Additional Evidence (extend)
-*Source: [[2026-03-27-blueorigin-new-glenn-manufacturing-odc-ambitions]] | Added: 2026-03-27*
+*Source: 2026-03-27-blueorigin-new-glenn-manufacturing-odc-ambitions | Added: 2026-03-27*
 
 Blue Origin is attempting to replicate the SpaceX/Starlink vertical integration model with New Glenn + Project Sunrise (51,600 satellite ODC constellation). Manufacturing rate of 1 rocket/month with 12-24 launch target for 2026 shows serious infrastructure investment, but the gap between manufacturing capability and launch cadence (only 2 flights in 2025, NG-3 delayed as of March 2026) reveals that building the vertical integration infrastructure is insufficient—operational execution at scale is the binding constraint.
 

domains/space-development/Starcloud is the first company to operate a datacenter-grade GPU in orbit but faces an existential dependency on SpaceX for launches while SpaceX builds a competing million-satellite constellation.md

@@ -6,16 +6,16 @@ confidence: experimental
 source: "Astra, web research compilation including CNBC, GeekWire, DCD, IEEE Spectrum, TechCrunch February 2026"
 created: 2026-02-17
 depends_on:
-  - "orbital data centers are the most speculative near-term space application but the convergence of AI compute demand and falling launch costs attracts serious players"
+- orbital data centers are the most speculative near-term space application but the convergence of AI compute demand and falling launch costs attracts serious players
-  - "on-orbit processing of satellite data is the proven near-term use case for space compute because it avoids bandwidth and thermal bottlenecks simultaneously"
+- on-orbit processing of satellite data is the proven near-term use case for space compute because it avoids bandwidth and thermal bottlenecks simultaneously
-  - "SpaceX vertical integration across launch broadband and manufacturing creates compounding cost advantages that no competitor can replicate piecemeal"
+- SpaceX vertical integration across launch broadband and manufacturing creates compounding cost advantages that no competitor can replicate piecemeal
 related:
-  - "Orbital data center deployment follows a three-tier launch vehicle activation sequence (rideshare → dedicated → constellation) where each tier unlocks an order-of-magnitude increase in compute scale"
+- Orbital data center deployment follows a three-tier launch vehicle activation sequence (rideshare → dedicated → constellation) where each tier unlocks an order-of-magnitude increase in compute scale
 reweave_edges:
-  - "Orbital data center deployment follows a three-tier launch vehicle activation sequence (rideshare → dedicated → constellation) where each tier unlocks an order-of-magnitude increase in compute scale|related|2026-04-04"
+- Orbital data center deployment follows a three-tier launch vehicle activation sequence (rideshare → dedicated → constellation) where each tier unlocks an order-of-magnitude increase in compute scale|related|2026-04-04
-  - "Starcloud|supports|2026-04-04"
+- Starcloud|supports|2026-04-04
 supports:
-  - "Starcloud"
+- Starcloud
 ---
 
 # Starcloud is the first company to operate a datacenter-grade GPU in orbit but faces an existential dependency on SpaceX for launches while SpaceX builds a competing million-satellite constellation
@@ -59,4 +59,4 @@ Relevant Notes:
 - [[SpaceX vertical integration across launch broadband and manufacturing creates compounding cost advantages that no competitor can replicate piecemeal]] — SpaceX controls launch, networking, and is building a competing product
 
 Topics:
-- [[space exploration and development]]
+- space exploration and development

domains/space-development/asteroid mining economics split into three distinct business models with water-for-propellant viable near-term and metals-for-Earth-return decades away.md

@@ -5,15 +5,16 @@ description: "Model A (water for orbital propellant) closes at $10K-50K/kg avoid
 confidence: likely
 source: "Astra, web research compilation February 2026"
 created: 2026-03-20
-challenged_by: ["falling launch costs may undercut Model A economics if Earth-launched water becomes cheaper than asteroid-derived water"]
+challenged_by:
+- falling launch costs may undercut Model A economics if Earth-launched water becomes cheaper than asteroid-derived water
 related:
-  - "asteroid mining and orbital habitats should be prioritized over planetary colonization because gravity wells are the binding constraint on opening the solar system to humanity"
+- asteroid mining and orbital habitats should be prioritized over planetary colonization because gravity wells are the binding constraint on opening the solar system to humanity
-  - "lunar resource extraction economics require equipment mass ratios under 50 tons per ton of mined material at projected 1M per ton delivery costs"
+- lunar resource extraction economics require equipment mass ratios under 50 tons per ton of mined material at projected 1M per ton delivery costs
-  - "the asteroid precious metals price paradox means mining success at scale collapses the prices that justify the mining"
+- the asteroid precious metals price paradox means mining success at scale collapses the prices that justify the mining
 reweave_edges:
-  - "asteroid mining and orbital habitats should be prioritized over planetary colonization because gravity wells are the binding constraint on opening the solar system to humanity|related|2026-04-04"
+- asteroid mining and orbital habitats should be prioritized over planetary colonization because gravity wells are the binding constraint on opening the solar system to humanity|related|2026-04-04
-  - "lunar resource extraction economics require equipment mass ratios under 50 tons per ton of mined material at projected 1M per ton delivery costs|related|2026-04-04"
+- lunar resource extraction economics require equipment mass ratios under 50 tons per ton of mined material at projected 1M per ton delivery costs|related|2026-04-04
-  - "the asteroid precious metals price paradox means mining success at scale collapses the prices that justify the mining|related|2026-04-04"
+- the asteroid precious metals price paradox means mining success at scale collapses the prices that justify the mining|related|2026-04-04
 ---
 
 # Asteroid mining economics split into three distinct business models with water-for-propellant viable near-term and metals-for-Earth-return decades away

domains/space-development/asteroid mining technology readiness drops sharply after prospecting with anchoring at TRL 2-3 and zero-gravity refining at TRL 1-2.md

@@ -6,11 +6,11 @@ confidence: likely
 source: "Astra, web research compilation February 2026; NASA TRL assessments"
 created: 2026-02-17
 depends_on:
-  - "asteroid mining second wave succeeds where the first failed because launch costs fell 10x spacecraft costs fell 30x and real customers now exist"
+- asteroid mining second wave succeeds where the first failed because launch costs fell 10x spacecraft costs fell 30x and real customers now exist
 related:
-  - "asteroid mining and orbital habitats should be prioritized over planetary colonization because gravity wells are the binding constraint on opening the solar system to humanity"
+- asteroid mining and orbital habitats should be prioritized over planetary colonization because gravity wells are the binding constraint on opening the solar system to humanity
 reweave_edges:
-  - "asteroid mining and orbital habitats should be prioritized over planetary colonization because gravity wells are the binding constraint on opening the solar system to humanity|related|2026-04-04"
+- asteroid mining and orbital habitats should be prioritized over planetary colonization because gravity wells are the binding constraint on opening the solar system to humanity|related|2026-04-04
 ---
 
 # Asteroid mining technology readiness drops sharply after prospecting with anchoring at TRL 2-3 and zero-gravity refining at TRL 1-2
@@ -40,4 +40,4 @@ Relevant Notes:
 - [[microgravity eliminates convection sedimentation and container effects producing measurably superior materials across fiber optics pharmaceuticals and semiconductors]] — microgravity is an advantage for manufacturing but a fundamental problem for mining
 
 Topics:
-- [[space exploration and development]]
+- space exploration and development

domains/space-development/commercial space stations are the next infrastructure bet as ISS retirement creates a void that 4 companies are racing to fill by 2030.md

@@ -5,11 +5,12 @@ description: "Axiom (PPTM launching 2027), Vast (Haven-1 slipped to Q1 2027), St
 confidence: likely
 source: "Astra synthesis from NASA Commercial LEO Destinations program, Axiom Space funding ($605M+), Vast Haven-1 timeline, ISS Deorbit Vehicle contract ($843M to SpaceX), MIT Technology Review 2026 Breakthrough Technologies"
 created: 2026-03-08
-challenged_by: "Timeline slippage threatens a gap in continuous human orbital presence (unbroken since November 2000). Axiom's September 2024 cash crisis and down round shows how fragile commercial station timelines are. If none of the four achieve operational capability before ISS deorbits in 2031, the US could face its first period without permanent crewed LEO presence in 25 years."
+challenged_by:
+- Timeline slippage threatens a gap in continuous human orbital presence (unbroken since November 2000). Axiom's September 2024 cash crisis and down round shows how fragile commercial station timelines are. If none of the four achieve operational capability before ISS deorbits in 2031, the US could face its first period without permanent crewed LEO presence in 25 years.
 supports:
-  - "Vast is building the first commercial space station with Haven 1 launching 2027 funded by Jed McCaleb 1B personal commitment and targeting artificial gravity stations by the 2030s"
+- Vast is building the first commercial space station with Haven 1 launching 2027 funded by Jed McCaleb 1B personal commitment and targeting artificial gravity stations by the 2030s
 reweave_edges:
-  - "Vast is building the first commercial space station with Haven 1 launching 2027 funded by Jed McCaleb 1B personal commitment and targeting artificial gravity stations by the 2030s|supports|2026-04-04"
+- Vast is building the first commercial space station with Haven 1 launching 2027 funded by Jed McCaleb 1B personal commitment and targeting artificial gravity stations by the 2030s|supports|2026-04-04
 ---
 
 # commercial space stations are the next infrastructure bet as ISS retirement creates a void that 4 companies are racing to fill by 2030
@@ -29,44 +30,44 @@ The attractor state is a marketplace of orbital platforms serving manufacturing,
 
 
 ### Additional Evidence (challenge)
-*Source: [[2026-03-00-commercial-stations-haven1-slip-orbital-reef-delays]] | Added: 2026-03-19*
+*Source: 2026-03-00-commercial-stations-haven1-slip-orbital-reef-delays | Added: 2026-03-19*
 
 Haven-1 has slipped from 2026 to 2027 (second delay), with first crewed mission now targeting summer 2027. Orbital Reef faces reported funding constraints at Blue Origin despite passing System Definition Review. Only Axiom remains on schedule with Hab One targeting 2026 ISS attachment. The ISS deorbit remains fixed at 2031, meaning the operational overlap window for knowledge transfer is compressing from 5+ years to potentially 4 years or less. This timeline slippage extends even to commercial programs with private capital, suggesting Pattern 2 (institutional timeline slippage) applies beyond government programs.
 
 ---
 
 ### Additional Evidence (challenge)
-*Source: [[2026-01-21-haven1-delay-2027-manufacturing-pace]] | Added: 2026-03-21*
+*Source: 2026-01-21-haven1-delay-2027-manufacturing-pace | Added: 2026-03-21*
 
 Haven-1, the first privately-funded commercial station attempt, has slipped 6 months (mid-2026 to Q1 2027) due to life support and thermal control integration pace. The delay is explicitly NOT launch-cost-related — Falcon 9 is available and affordable. This suggests the 'race to 2030' may be constrained more by technology maturation timelines than by capital or launch access, potentially widening the gap between first-mover aspirations and operational reality.
 
 ### Additional Evidence (extend)
-*Source: [[2026-02-26-starlab-ccdr-full-scale-development]] | Added: 2026-03-21*
+*Source: 2026-02-26-starlab-ccdr-full-scale-development | Added: 2026-03-21*
 
 Starlab completed Commercial Critical Design Review (CCDR) with NASA in February 2026, transitioning from design to full-scale development. This is the first commercial station program to reach CCDR milestone. Timeline: CDR expected late 2026, hardware fabrication 2026-2027, integration 2027-2028, single-flight Starship launch in 2028. The 2028 launch gives Starlab a 3-year operational window before ISS deorbits in 2031. Partnership consortium includes Voyager (prime, NYSE:VOYG), Airbus (inflatable habitat), Mitsubishi, MDA Space (robotics), Palantir (operations/data), Northrop Grumman (integration). Station designed for 12 simultaneous researchers. Development costs projected at $2.8-3.3B total, with $217.5M NASA Phase 1 funding and $15M Texas Space Commission funding. Critical constraint: NASA Phase 2 funding frozen as of January 28, 2026, creating funding gap of potentially $500M-$750M that private consortium must fill.
 
 ### Additional Evidence (extend)
-*Source: [[2026-02-12-nasa-vast-axiom-pam5-pam6-iss]] | Added: 2026-03-22*
+*Source: 2026-02-12-nasa-vast-axiom-pam5-pam6-iss | Added: 2026-03-22*
 
 NASA awarded Axiom Mission 5 and Vast's first PAM in February 2026, demonstrating active government demand for commercial station services even before stations are operational. Vast's PAM award before Haven-1 launches shows NASA creating operational experience and revenue streams that reduce commercial station development risk.
 
 ### Additional Evidence (extend)
-*Source: [[2026-03-22-voyager-technologies-q4-fy2025-starlab-financials]] | Added: 2026-03-22*
+*Source: 2026-03-22-voyager-technologies-q4-fy2025-starlab-financials | Added: 2026-03-22*
 
 Voyager Technologies completed Starlab's commercial Critical Design Review (CCDR) in 2025, marking 31 total milestones completed with $183.2M NASA cash received inception-to-date. The company maintains $704.7M liquidity (+15% sequential) specifically to bridge the design-to-manufacturing transition, demonstrating that commercial station developers are actively progressing through development gates with substantial capital reserves.
 
 ### Additional Evidence (challenge)
-*Source: [[2026-01-28-nasa-cld-phase2-frozen-saa-revised-approach]] | Added: 2026-03-23*
+*Source: 2026-01-28-nasa-cld-phase2-frozen-saa-revised-approach | Added: 2026-03-23*
 
 NASA's January 28, 2026 Phase 2 CLD freeze placed the entire commercial station sector on hold indefinitely, and the July 2025 requirement reduction from 'permanently crewed' to 'crew-tended' suggests programs cannot meet the original operational bar. The freeze converts the 2030 timeline from a target to an open question, and the requirement softening reveals capability gaps that weren't visible in Phase 1 awards.
 
 ### Additional Evidence (challenge)
-*Source: [[2026-01-28-nasa-cld-phase2-frozen-saa-revised-approach]] | Added: 2026-03-24*
+*Source: 2026-01-28-nasa-cld-phase2-frozen-saa-revised-approach | Added: 2026-03-24*
 
 NASA Phase 2 CLD program frozen January 28, 2026 with no replacement timeline, converting $1-1.5B anticipated funding into indefinite risk. Requirements previously softened from 'permanently crewed' to 'crew-tended' in July 2025, suggesting original operational bar was unachievable. Phil McAlister characterized freeze as 'schedule risk' not 'safety risk,' implying programs can wait but cannot proceed without NASA anchor funding.
 
 ### Additional Evidence (extend)
-*Source: [[2026-03-27-nasa-authorization-act-iss-overlap-mandate]] | Added: 2026-03-27*
+*Source: 2026-03-27-nasa-authorization-act-iss-overlap-mandate | Added: 2026-03-27*
 
 The NASA Authorization Act of 2026 overlap mandate creates a policy-engineered Gate 2 by requiring ISS to operate alongside a fully operational commercial station for one year with 180 days of concurrent crew operations. This transforms the 'void' from a market opportunity into a mandated transition condition with specific technical requirements and government anchor tenant guarantees.
 

domains/space-development/commercial-odc-interoperability-with-sda-standards-reflects-deliberate-dual-use-orbital-compute-architecture.md

@@ -11,9 +11,9 @@ scope: structural
 sourcer: National Defense Magazine
 related_claims: ["[[defense spending is the new catalyst for space investment with US Space Force budget jumping 39 percent in one year to 40 billion]]", "[[governments are transitioning from space system builders to space service buyers which structurally advantages nimble commercial providers]]"]
 supports:
-  - "Military and commercial space architectures are converging on the same distributed orbital compute design because both require low-latency data processing across multi-orbit satellite networks"
+- Military and commercial space architectures are converging on the same distributed orbital compute design because both require low-latency data processing across multi-orbit satellite networks
 reweave_edges:
-  - "Military and commercial space architectures are converging on the same distributed orbital compute design because both require low-latency data processing across multi-orbit satellite networks|supports|2026-04-04"
+- Military and commercial space architectures are converging on the same distributed orbital compute design because both require low-latency data processing across multi-orbit satellite networks|supports|2026-04-04
 ---
 
 # Commercial orbital data center interoperability with SDA Tranche 1 optical communications standards reflects deliberate architectural alignment between commercial ODC and operational defense space computing

domains/space-development/europe-space-launch-strategic-irrelevance-without-starship-class-capability.md

@@ -7,9 +7,9 @@ source: "German Aerospace Center (DLR) assessment via Phys.org, March 2026"
 created: 2026-03-11
 secondary_domains: [grand-strategy]
 related:
-  - "China is the only credible peer competitor in space with comprehensive capabilities and state directed acceleration closing the reusability gap in 5 8 years"
+- China is the only credible peer competitor in space with comprehensive capabilities and state directed acceleration closing the reusability gap in 5 8 years
 reweave_edges:
-  - "China is the only credible peer competitor in space with comprehensive capabilities and state directed acceleration closing the reusability gap in 5 8 years|related|2026-04-04"
+- China is the only credible peer competitor in space with comprehensive capabilities and state directed acceleration closing the reusability gap in 5 8 years|related|2026-04-04
 ---
 
 # European aerospace institutions assess that Starship-class capability is strategically necessary, not merely advantageous

domains/space-development/falling launch costs paradoxically both enable and threaten in-space resource utilization by making infrastructure affordable while competing with the end product.md

@@ -5,11 +5,12 @@ description: "Starship at $10-100/kg makes ISRU prospecting missions viable but
 confidence: likely
 source: "Astra synthesis from Falcon 9 vs Starship cost trajectories, orbital mechanics delta-v budgets, ISRU cost modeling"
 created: 2026-03-07
-challenged_by: "The geographic resolution may be too clean. Even at lunar distances, if Starship achieves the low end of cost projections ($10-30/kg to LEO), the additional delta-v cost to deliver water to the lunar surface from Earth may be competitive with extracting it locally — especially if lunar ISRU requires heavy upfront infrastructure investment that amortizes slowly."
+challenged_by:
+- The geographic resolution may be too clean. Even at lunar distances, if Starship achieves the low end of cost projections ($10-30/kg to LEO), the additional delta-v cost to deliver water to the lunar surface from Earth may be competitive with extracting it locally — especially if lunar ISRU requires heavy upfront infrastructure investment that amortizes slowly.
 related:
-  - "lunar resource extraction economics require equipment mass ratios under 50 tons per ton of mined material at projected 1M per ton delivery costs"
+- lunar resource extraction economics require equipment mass ratios under 50 tons per ton of mined material at projected 1M per ton delivery costs
 reweave_edges:
-  - "lunar resource extraction economics require equipment mass ratios under 50 tons per ton of mined material at projected 1M per ton delivery costs|related|2026-04-04"
+- lunar resource extraction economics require equipment mass ratios under 50 tons per ton of mined material at projected 1M per ton delivery costs|related|2026-04-04
 ---
 
 # falling launch costs paradoxically both enable and threaten in-space resource utilization by making infrastructure affordable while competing with the end product
@@ -27,43 +28,43 @@ The investment implication is that ISRU businesses should be evaluated not again
 
 
 ### Additional Evidence (extend)
-*Source: [[2026-03-18-interlune-doe-helium3-purchase]] | Added: 2026-03-18*
+*Source: 2026-03-18-interlune-doe-helium3-purchase | Added: 2026-03-18*
 
 Helium-3 extraction avoids the launch cost competition problem that threatens water-for-propellant economics because helium-3's terrestrial scarcity and quantum computing demand create a market where lunar extraction competes against constrained Earth supply rather than against launch services. This suggests resources with high Earth-side value and limited terrestrial supply may be more economically viable than resources primarily valuable for in-space use.
 
 
 ### Additional Evidence (extend)
-*Source: [[2026-03-18-spacenews-lunar-economy-resources-reactors]] | Added: 2026-03-18*
+*Source: 2026-03-18-spacenews-lunar-economy-resources-reactors | Added: 2026-03-18*
 
 The helium-3 quantum computing demand creates a case where lunar resources have Earth-side markets that launch cost reductions cannot compete with, because the resource literally doesn't exist on Earth in sufficient quantities. This represents a boundary condition where the paradox doesn't apply: when the resource is unavailable terrestrially, launch costs only affect the extraction economics, not the market viability.
 
 
 ### Additional Evidence (extend)
-*Source: [[2026-03-18-interlune-afwerx-terrestrial-he3-extraction]] | Added: 2026-03-18*
+*Source: 2026-03-18-interlune-afwerx-terrestrial-he3-extraction | Added: 2026-03-18*
 
 Interlune is developing terrestrial helium-3 extraction via cryogenic distillation from natural helium gas streams under a $1.25M AFWERX contract. This represents a direct terrestrial supply alternative to lunar He-3, not just cheaper launch competing with space resources. The He-3 concentration in natural helium (~0.0001% He-3/He-4 ratio) limits terrestrial scale, but proves the extraction technology works and creates a dual-use hedge for Interlune's lunar thesis.
 
 
 ### Additional Evidence (challenge)
-*Source: [[2026-03-18-interlune-afwerx-terrestrial-he3-extraction]] | Added: 2026-03-18*
+*Source: 2026-03-18-interlune-afwerx-terrestrial-he3-extraction | Added: 2026-03-18*
 
 Interlune's terrestrial He-3 extraction program suggests the threat to lunar resource economics may come from improved terrestrial extraction technology rather than just cheaper launch. If cryogenic distillation becomes economical at scale, the scarcity premium driving lunar He-3 prices could collapse before lunar infrastructure is built. This is a supply-side substitution risk, not a launch cost arbitrage.
 
 
 ### Additional Evidence (extend)
-*Source: [[2026-02-00-euca2al9-china-nature-adr-he3-replacement]] | Added: 2026-03-19*
+*Source: 2026-02-00-euca2al9-china-nature-adr-he3-replacement | Added: 2026-03-19*
 
 EuCo2Al9 ADR materials create a terrestrial alternative to lunar He-3 extraction, demonstrating the substitution risk pattern at the materials level. If rare-earth ADR can achieve qubit-temperature cooling without He-3, it eliminates the quantum computing demand driver for lunar He-3 mining before space infrastructure costs fall enough to make extraction economical. This extends the launch cost paradox from 'cheap launch competes with space resources' to 'terrestrial material substitution races against space infrastructure deployment.'
 
 
 ### Additional Evidence (extend)
-*Source: [[2026-01-29-interlune-5m-safe-500m-contracts-2026-milestones]] | Added: 2026-03-19*
+*Source: 2026-01-29-interlune-5m-safe-500m-contracts-2026-milestones | Added: 2026-03-19*
 
 Interlune's milestone-gated financing structure suggests investors are managing the 'launch cost competition' risk by deferring capital deployment until technology proves out. The $23M raised vs. $500M+ contracts ratio shows investors won't fund full-scale infrastructure until extraction is demonstrated, precisely because falling launch costs create uncertainty about whether lunar He-3 can compete with terrestrial alternatives or Earth-launched supplies.
 
 
 ### Additional Evidence (extend)
-*Source: [[2025-07-30-jacs-kyb3f10-adr-27mK-helium-free]] | Added: 2026-03-20*
+*Source: 2025-07-30-jacs-kyb3f10-adr-27mK-helium-free | Added: 2026-03-20*
 
 ADR systems using frustrated magnets (KYb3F10) achieved 27.2 mK in July 2025, approaching superconducting qubit temperatures and demonstrating that He-3 substitution technology is advancing faster than previously assumed. The gap between research ADR (27.2 mK) and qubit requirements (10-15 mK) is now only ~2x, compared to commercial ADR at 100-300 mK (4-10x gap). This accelerates the substitution timeline for He-3 demand in quantum computing, the primary terrestrial application driving cislunar He-3 extraction economics.
 

domains/space-development/golden-dome-missile-defense-requires-orbital-compute-because-ground-transmission-latency-exceeds-interception-decision-windows.md

@@ -11,11 +11,11 @@ scope: causal
 sourcer: "Air & Space Forces Magazine"
 related_claims: ["[[defense spending is the new catalyst for space investment with US Space Force budget jumping 39 percent in one year to 40 billion]]", "[[governments are transitioning from space system builders to space service buyers which structurally advantages nimble commercial providers]]", "[[space governance gaps are widening not narrowing because technology advances exponentially while institutional design advances linearly]]"]
 supports:
-  - "Golden Dome's Space Data Network requires distributed orbital data processing because sensor-to-shooter missile defense latency constraints make ground-based processing architecturally infeasible"
+- Golden Dome's Space Data Network requires distributed orbital data processing because sensor-to-shooter missile defense latency constraints make ground-based processing architecturally infeasible
-  - "The Space Development Agency's PWSA is already running battle management algorithms in space as an operational capability, establishing defense as the first deployed user of orbital computing at constellation scale"
+- The Space Development Agency's PWSA is already running battle management algorithms in space as an operational capability, establishing defense as the first deployed user of orbital computing at constellation scale
 reweave_edges:
-  - "Golden Dome's Space Data Network requires distributed orbital data processing because sensor-to-shooter missile defense latency constraints make ground-based processing architecturally infeasible|supports|2026-04-04"
+- Golden Dome's Space Data Network requires distributed orbital data processing because sensor-to-shooter missile defense latency constraints make ground-based processing architecturally infeasible|supports|2026-04-04
-  - "The Space Development Agency's PWSA is already running battle management algorithms in space as an operational capability, establishing defense as the first deployed user of orbital computing at constellation scale|supports|2026-04-04"
+- The Space Development Agency's PWSA is already running battle management algorithms in space as an operational capability, establishing defense as the first deployed user of orbital computing at constellation scale|supports|2026-04-04
 ---
 
 # Golden Dome missile defense requires orbital compute because ground-based processing transmission latency exceeds time-critical decision windows for missile interception

domains/space-development/golden-dome-space-data-network-requires-orbital-compute-for-latency-constraints.md

@@ -11,11 +11,11 @@ scope: structural
 sourcer: Breaking Defense
 related_claims: ["[[defense spending is the new catalyst for space investment with US Space Force budget jumping 39 percent in one year to 40 billion]]"]
 supports:
-  - "Golden Dome missile defense requires orbital compute because ground-based processing transmission latency exceeds time-critical decision windows for missile interception"
+- Golden Dome missile defense requires orbital compute because ground-based processing transmission latency exceeds time-critical decision windows for missile interception
-  - "Military and commercial space architectures are converging on the same distributed orbital compute design because both require low-latency data processing across multi-orbit satellite networks"
+- Military and commercial space architectures are converging on the same distributed orbital compute design because both require low-latency data processing across multi-orbit satellite networks
 reweave_edges:
-  - "Golden Dome missile defense requires orbital compute because ground-based processing transmission latency exceeds time-critical decision windows for missile interception|supports|2026-04-04"
+- Golden Dome missile defense requires orbital compute because ground-based processing transmission latency exceeds time-critical decision windows for missile interception|supports|2026-04-04
-  - "Military and commercial space architectures are converging on the same distributed orbital compute design because both require low-latency data processing across multi-orbit satellite networks|supports|2026-04-04"
+- Military and commercial space architectures are converging on the same distributed orbital compute design because both require low-latency data processing across multi-orbit satellite networks|supports|2026-04-04
 ---
 
 # Golden Dome's Space Data Network requires distributed orbital data processing because sensor-to-shooter missile defense latency constraints make ground-based processing architecturally infeasible

domains/space-development/launch cost reduction is the keystone variable that unlocks every downstream space industry at specific price thresholds.md

@@ -6,16 +6,16 @@ confidence: likely
 source: "Astra, web research compilation February 2026"
 created: 2026-02-17
 depends_on:
-  - "attractor states provide gravitational reference points for capital allocation during structural industry change"
+- attractor states provide gravitational reference points for capital allocation during structural industry change
 secondary_domains:
   - teleological-economics
 related:
-  - "gate 2 demand formation mechanisms are cost parity constrained with government floors cost independent concentrated buyers requiring 2 3x proximity and organic markets requiring full parity"
+- gate 2 demand formation mechanisms are cost parity constrained with government floors cost independent concentrated buyers requiring 2 3x proximity and organic markets requiring full parity
 reweave_edges:
-  - "gate 2 demand formation mechanisms are cost parity constrained with government floors cost independent concentrated buyers requiring 2 3x proximity and organic markets requiring full parity|related|2026-04-04"
+- gate 2 demand formation mechanisms are cost parity constrained with government floors cost independent concentrated buyers requiring 2 3x proximity and organic markets requiring full parity|related|2026-04-04
-  - "the megastructure launch sequence from skyhooks to Lofstrom loops to orbital rings may be economically self bootstrapping if each stage generates sufficient returns to fund the next|supports|2026-04-04"
+- the megastructure launch sequence from skyhooks to Lofstrom loops to orbital rings may be economically self bootstrapping if each stage generates sufficient returns to fund the next|supports|2026-04-04
 supports:
-  - "the megastructure launch sequence from skyhooks to Lofstrom loops to orbital rings may be economically self bootstrapping if each stage generates sufficient returns to fund the next"
+- the megastructure launch sequence from skyhooks to Lofstrom loops to orbital rings may be economically self bootstrapping if each stage generates sufficient returns to fund the next
 ---
 
 # launch cost reduction is the keystone variable that unlocks every downstream space industry at specific price thresholds
@@ -33,17 +33,17 @@ The keystone variable framing implies a single bottleneck, but space development
 ---
 
 ### Additional Evidence (extend)
-*Source: [[2026-01-21-haven1-delay-2027-manufacturing-pace]] | Added: 2026-03-21*
+*Source: 2026-01-21-haven1-delay-2027-manufacturing-pace | Added: 2026-03-21*
 
 Haven-1's delay provides a boundary condition: once launch cost crosses below a threshold (~$67M for Falcon 9), the binding constraint shifts to technology development pace (life support integration, avionics, thermal control). For commercial stations in 2026, launch cost is no longer the keystone variable — it has been solved. The new keystone is knowledge embodiment in complex habitation systems.
 
 ### Additional Evidence (confirm)
-*Source: [[2026-03-27-starship-falcon9-cost-2026-commercial-operations]] | Added: 2026-03-27*
+*Source: 2026-03-27-starship-falcon9-cost-2026-commercial-operations | Added: 2026-03-27*
 
 As of March 2026, Starship operational cost is $1,600/kg, creating an 8x gap to the $200/kg ODC threshold. No commercial ODC operations have materialized despite technical readiness, consistent with the thesis that specific cost thresholds gate sector emergence.
 
 ### Additional Evidence (extend)
-*Source: [[2026-03-28-keeptrack-starship-v3-april-2026]] | Added: 2026-03-28*
+*Source: 2026-03-28-keeptrack-starship-v3-april-2026 | Added: 2026-03-28*
 
 The gap between Starship entering commercial service (2027 with Superbird-9) and clearing specific price thresholds creates a multi-year lag between launch availability and sector activation. Current $1,600/kg operational cost vs. $200/kg ODC threshold demonstrates that vehicle availability does not equal threshold crossing—the cost reduction curve has its own timeline independent of commercial service debut.
 
@@ -56,4 +56,4 @@ Relevant Notes:
 - [[the space launch cost trajectory is a phase transition not a gradual decline analogous to sail-to-steam in maritime transport]] — the framing for why this is discontinuous structural change
 
 Topics:
-- [[space exploration and development]]
+- space exploration and development

domains/space-development/military-commercial-space-architecture-convergence-creates-dual-use-orbital-infrastructure.md

@@ -11,11 +11,11 @@ scope: structural
 sourcer: Breaking Defense
 related_claims: ["[[defense spending is the new catalyst for space investment with US Space Force budget jumping 39 percent in one year to 40 billion]]", "[[governments are transitioning from space system builders to space service buyers which structurally advantages nimble commercial providers]]"]
 supports:
-  - "Commercial orbital data center interoperability with SDA Tranche 1 optical communications standards reflects deliberate architectural alignment between commercial ODC and operational defense space computing"
+- Commercial orbital data center interoperability with SDA Tranche 1 optical communications standards reflects deliberate architectural alignment between commercial ODC and operational defense space computing
-  - "Golden Dome's Space Data Network requires distributed orbital data processing because sensor-to-shooter missile defense latency constraints make ground-based processing architecturally infeasible"
+- Golden Dome's Space Data Network requires distributed orbital data processing because sensor-to-shooter missile defense latency constraints make ground-based processing architecturally infeasible
 reweave_edges:
-  - "Commercial orbital data center interoperability with SDA Tranche 1 optical communications standards reflects deliberate architectural alignment between commercial ODC and operational defense space computing|supports|2026-04-04"
+- Commercial orbital data center interoperability with SDA Tranche 1 optical communications standards reflects deliberate architectural alignment between commercial ODC and operational defense space computing|supports|2026-04-04
-  - "Golden Dome's Space Data Network requires distributed orbital data processing because sensor-to-shooter missile defense latency constraints make ground-based processing architecturally infeasible|supports|2026-04-04"
+- Golden Dome's Space Data Network requires distributed orbital data processing because sensor-to-shooter missile defense latency constraints make ground-based processing architecturally infeasible|supports|2026-04-04
 ---
 
 # Military and commercial space architectures are converging on the same distributed orbital compute design because both require low-latency data processing across multi-orbit satellite networks

domains/space-development/orbital data centers are the most speculative near-term space application but the convergence of AI compute demand and falling launch costs attracts serious players.md

@@ -8,23 +8,23 @@ created: 2026-02-17
 secondary_domains:
   - critical-systems
 depends_on:
-  - "space-based computing at datacenter scale is blocked by thermal physics because radiative cooling in vacuum requires surface areas that grow faster than compute density"
+- space-based computing at datacenter scale is blocked by thermal physics because radiative cooling in vacuum requires surface areas that grow faster than compute density
-  - "Starship achieving routine operations at sub-100 dollars per kg is the single largest enabling condition for the entire space industrial economy"
+- Starship achieving routine operations at sub-100 dollars per kg is the single largest enabling condition for the entire space industrial economy
 supports:
-  - "Starcloud is the first company to operate a datacenter grade GPU in orbit but faces an existential dependency on SpaceX for launches while SpaceX builds a competing million satellite constellation"
+- Starcloud is the first company to operate a datacenter grade GPU in orbit but faces an existential dependency on SpaceX for launches while SpaceX builds a competing million satellite constellation
-  - "orbital compute hardware cannot be serviced making every component either radiation hardened redundant or disposable with failed hardware becoming debris or requiring expensive deorbit"
+- orbital compute hardware cannot be serviced making every component either radiation hardened redundant or disposable with failed hardware becoming debris or requiring expensive deorbit
-  - "Orbital data center deployment follows a three-tier launch vehicle activation sequence (rideshare → dedicated → constellation) where each tier unlocks an order-of-magnitude increase in compute scale"
+- Orbital data center deployment follows a three-tier launch vehicle activation sequence (rideshare → dedicated → constellation) where each tier unlocks an order-of-magnitude increase in compute scale
-  - "solar irradiance in LEO delivers 8 10x ground based solar power with near continuous availability in sun synchronous orbits making orbital compute power abundant where terrestrial facilities are power starved"
+- solar irradiance in LEO delivers 8 10x ground based solar power with near continuous availability in sun synchronous orbits making orbital compute power abundant where terrestrial facilities are power starved
-  - "Starcloud"
+- Starcloud
 reweave_edges:
-  - "Starcloud is the first company to operate a datacenter grade GPU in orbit but faces an existential dependency on SpaceX for launches while SpaceX builds a competing million satellite constellation|supports|2026-04-04"
+- Starcloud is the first company to operate a datacenter grade GPU in orbit but faces an existential dependency on SpaceX for launches while SpaceX builds a competing million satellite constellation|supports|2026-04-04
-  - "orbital compute hardware cannot be serviced making every component either radiation hardened redundant or disposable with failed hardware becoming debris or requiring expensive deorbit|supports|2026-04-04"
+- orbital compute hardware cannot be serviced making every component either radiation hardened redundant or disposable with failed hardware becoming debris or requiring expensive deorbit|supports|2026-04-04
-  - "Orbital data center deployment follows a three-tier launch vehicle activation sequence (rideshare → dedicated → constellation) where each tier unlocks an order-of-magnitude increase in compute scale|supports|2026-04-04"
+- Orbital data center deployment follows a three-tier launch vehicle activation sequence (rideshare → dedicated → constellation) where each tier unlocks an order-of-magnitude increase in compute scale|supports|2026-04-04
-  - "Radiative cooling in space is a cost advantage over terrestrial data centers, not merely a constraint to overcome, with claimed cooling costs of $0.002-0.005/kWh versus terrestrial active cooling|related|2026-04-04"
+- Radiative cooling in space is a cost advantage over terrestrial data centers, not merely a constraint to overcome, with claimed cooling costs of $0.002-0.005/kWh versus terrestrial active cooling|related|2026-04-04
-  - "solar irradiance in LEO delivers 8 10x ground based solar power with near continuous availability in sun synchronous orbits making orbital compute power abundant where terrestrial facilities are power starved|supports|2026-04-04"
+- solar irradiance in LEO delivers 8 10x ground based solar power with near continuous availability in sun synchronous orbits making orbital compute power abundant where terrestrial facilities are power starved|supports|2026-04-04
-  - "Starcloud|supports|2026-04-04"
+- Starcloud|supports|2026-04-04
 related:
-  - "Radiative cooling in space is a cost advantage over terrestrial data centers, not merely a constraint to overcome, with claimed cooling costs of $0.002-0.005/kWh versus terrestrial active cooling"
+- Radiative cooling in space is a cost advantage over terrestrial data centers, not merely a constraint to overcome, with claimed cooling costs of $0.002-0.005/kWh versus terrestrial active cooling
 ---
 
 # Orbital data centers are the most speculative near-term space application but the convergence of AI compute demand and falling launch costs attracts serious players
@@ -52,4 +52,4 @@ Relevant Notes:
 - [[Starship achieving routine operations at sub-100 dollars per kg is the single largest enabling condition for the entire space industrial economy]] — orbital data centers require Starship-era launch costs
 
 Topics:
-- [[space exploration and development]]
+- space exploration and development

domains/space-development/orbital data centers require five enabling technologies to mature simultaneously and none currently exist at required readiness.md

@@ -6,15 +6,15 @@ confidence: likely
 source: "Astra, space data centers feasibility analysis February 2026; Google Project Suncatcher analysis"
 created: 2026-02-17
 depends_on:
-  - "space-based computing at datacenter scale is blocked by thermal physics because radiative cooling in vacuum requires surface areas that grow faster than compute density"
+- space-based computing at datacenter scale is blocked by thermal physics because radiative cooling in vacuum requires surface areas that grow faster than compute density
-  - "Starship achieving routine operations at sub-100 dollars per kg is the single largest enabling condition for the entire space industrial economy"
+- Starship achieving routine operations at sub-100 dollars per kg is the single largest enabling condition for the entire space industrial economy
 challenges:
-  - "Starcloud is the first company to operate a datacenter grade GPU in orbit but faces an existential dependency on SpaceX for launches while SpaceX builds a competing million satellite constellation"
+- Starcloud is the first company to operate a datacenter grade GPU in orbit but faces an existential dependency on SpaceX for launches while SpaceX builds a competing million satellite constellation
 reweave_edges:
-  - "Starcloud is the first company to operate a datacenter grade GPU in orbit but faces an existential dependency on SpaceX for launches while SpaceX builds a competing million satellite constellation|challenges|2026-04-04"
+- Starcloud is the first company to operate a datacenter grade GPU in orbit but faces an existential dependency on SpaceX for launches while SpaceX builds a competing million satellite constellation|challenges|2026-04-04
-  - "orbital compute hardware cannot be serviced making every component either radiation hardened redundant or disposable with failed hardware becoming debris or requiring expensive deorbit|related|2026-04-04"
+- orbital compute hardware cannot be serviced making every component either radiation hardened redundant or disposable with failed hardware becoming debris or requiring expensive deorbit|related|2026-04-04
 related:
-  - "orbital compute hardware cannot be serviced making every component either radiation hardened redundant or disposable with failed hardware becoming debris or requiring expensive deorbit"
+- orbital compute hardware cannot be serviced making every component either radiation hardened redundant or disposable with failed hardware becoming debris or requiring expensive deorbit
 ---
 
 # Orbital data centers require five enabling technologies to mature simultaneously and none currently exist at required readiness
@@ -49,4 +49,4 @@ Relevant Notes:
 - [[modern AI accelerators are more radiation-tolerant than expected because Google TPU testing showed no hard failures up to 15 krad suggesting consumer chips may survive LEO environments]] — technology #4 showing promising early results
 
 Topics:
-- [[space exploration and development]]
+- space exploration and development

domains/space-development/reusability without rapid turnaround and minimal refurbishment does not reduce launch costs as the Space Shuttle proved over 30 years.md

@@ -6,11 +6,11 @@ confidence: proven
 source: "NASA Space Shuttle program cost data ($1.5B per launch, 27,500 kg payload, $54,500/kg over 30 years of operations), SpaceX Falcon 9 reuse economics for contrast"
 created: 2026-03-07
 related:
-  - "China is the only credible peer competitor in space with comprehensive capabilities and state directed acceleration closing the reusability gap in 5 8 years"
+- China is the only credible peer competitor in space with comprehensive capabilities and state directed acceleration closing the reusability gap in 5 8 years
-  - "europe space launch strategic irrelevance without starship class capability"
+- europe space launch strategic irrelevance without starship class capability
 reweave_edges:
-  - "China is the only credible peer competitor in space with comprehensive capabilities and state directed acceleration closing the reusability gap in 5 8 years|related|2026-04-04"
+- China is the only credible peer competitor in space with comprehensive capabilities and state directed acceleration closing the reusability gap in 5 8 years|related|2026-04-04
-  - "europe space launch strategic irrelevance without starship class capability|related|2026-04-04"
+- europe space launch strategic irrelevance without starship class capability|related|2026-04-04
 ---
 
 # reusability without rapid turnaround and minimal refurbishment does not reduce launch costs as the Space Shuttle proved over 30 years
@@ -25,30 +25,30 @@ SpaceX's Falcon 9 demonstrated the correct approach with booster recovery requir
 
 
 ### Additional Evidence (extend)
-*Source: [[2026-03-18-blue-origin-ng3-booster-reuse]] | Added: 2026-03-18*
+*Source: 2026-03-18-blue-origin-ng3-booster-reuse | Added: 2026-03-18*
 
 Blue Origin's New Glenn booster achieved ~3 month turnaround for first reuse attempt (NG-2 Nov 2025 to NG-3 late Feb 2026), with booster designed for 25+ flights. This represents a significantly faster turnaround than Space Shuttle's multi-month refurbishment cycles, suggesting Blue Origin learned from Shuttle's operational failures.
 
 
 ### Additional Evidence (extend)
-*Source: [[2026-03-18-new-glenn-ng3-booster-reuse-pending]] | Added: 2026-03-18*
+*Source: 2026-03-18-new-glenn-ng3-booster-reuse-pending | Added: 2026-03-18*
 
 Blue Origin's New Glenn NG-3 mission demonstrates a ~3-month booster turnaround time (Nov 2025 landing to March 2026 relaunch). This is slower than SpaceX's best (<30 days) but faster than early Falcon 9 reuse cycles, providing a new data point on the turnaround spectrum between Space Shuttle (months of refurbishment) and mature SpaceX operations.
 
 ---
 
 ### Additional Evidence (extend)
-*Source: [[2026-03-19-spacex-starship-b19-partial-static-fire-10-engines]] | Added: 2026-03-25*
+*Source: 2026-03-19-spacex-starship-b19-partial-static-fire-10-engines | Added: 2026-03-25*
 
 V3 qualification timeline shows the challenge of validating new engine generations at scale. The 10-engine partial static fire (March 16) to 33-engine full static fire sequence demonstrates that even with successful engine startup, ground systems integration (GSE at new Pad 2) creates qualification bottlenecks. Each delay in V3 validation extends the timeline to operational reusability with Raptor 3.
 
 ### Additional Evidence (confirm)
-*Source: [[2026-03-27-blueorigin-new-glenn-manufacturing-odc-ambitions]] | Added: 2026-03-27*
+*Source: 2026-03-27-blueorigin-new-glenn-manufacturing-odc-ambitions | Added: 2026-03-27*
 
 Blue Origin's New Glenn program shows manufacturing rate (1/month) significantly exceeding launch cadence (2 total launches in 2025), with NG-3 still delayed as of March 2026. This demonstrates that building reusable hardware does not automatically translate to high-cadence operations—the operational knowledge (pad turnaround, refurbishment processes, flight software maturity) lags behind manufacturing capability.
 
 ### Additional Evidence (extend)
-*Source: [[2026-03-28-nasaspaceflight-new-glenn-manufacturing-odc-ambitions]] | Added: 2026-03-28*
+*Source: 2026-03-28-nasaspaceflight-new-glenn-manufacturing-odc-ambitions | Added: 2026-03-28*
 
 New Glenn NG-3 mission will attempt first booster reuse (reflying 'Never Tell Me The Odds' from NG-1), but the 15-month gap between NG-1 and NG-3 demonstrates that achieving reuse is separate from achieving rapid reuse. Even with a reusable booster available since January 2025, operational tempo remains the binding constraint on cost reduction through reuse economics.
 

domains/space-development/reusable-launch-convergence-creates-us-china-duopoly-in-heavy-lift.md

@@ -7,12 +7,12 @@ source: "European reusable launch program status via Phys.org, March 2026"
 created: 2026-03-11
 secondary_domains: [grand-strategy]
 related:
-  - "China is the only credible peer competitor in space with comprehensive capabilities and state directed acceleration closing the reusability gap in 5 8 years"
+- China is the only credible peer competitor in space with comprehensive capabilities and state directed acceleration closing the reusability gap in 5 8 years
 reweave_edges:
-  - "China is the only credible peer competitor in space with comprehensive capabilities and state directed acceleration closing the reusability gap in 5 8 years|related|2026-04-04"
+- China is the only credible peer competitor in space with comprehensive capabilities and state directed acceleration closing the reusability gap in 5 8 years|related|2026-04-04
-  - "europe space launch strategic irrelevance without starship class capability|supports|2026-04-04"
+- europe space launch strategic irrelevance without starship class capability|supports|2026-04-04
 supports:
-  - "europe space launch strategic irrelevance without starship class capability"
+- europe space launch strategic irrelevance without starship class capability
 ---
 
 # Reusability in heavy-lift launch may create a capability divide between operational programs and concept-stage competitors rather than diffusing globally
@@ -38,19 +38,19 @@ This is a snapshot of March 2026 program status, not a permanent structural cond
 
 
 ### Additional Evidence (challenge)
-*Source: [[2026-02-11-china-long-march-10-sea-landing]] | Added: 2026-03-16*
+*Source: 2026-02-11-china-long-march-10-sea-landing | Added: 2026-03-16*
 
 China demonstrated controlled first-stage sea landing on February 11, 2026, with Long March 10B reusable variant launching April 5, 2026. The reusability gap closed in ~2 years, not the 5-8 years previously estimated. This suggests state-directed industrial policy accelerates technology development faster than market-driven timelines predicted.
 
 
 ### Additional Evidence (extend)
-*Source: [[2026-02-11-china-long-march-10-sea-landing]] | Added: 2026-03-16*
+*Source: 2026-02-11-china-long-march-10-sea-landing | Added: 2026-03-16*
 
 China's recovery approach uses tethered wire/cable-net systems fundamentally different from SpaceX's tower catch or ship landing, demonstrating independent innovation trajectory rather than pure technology copying. The 25,000-ton 'Ling Hang Zhe' recovery ship with specialized cable gantry represents a distinct engineering solution optimized for sea-based operations.
 
 
 ### Additional Evidence (extend)
-*Source: [[2026-03-18-starship-flight12-v3-status]] | Added: 2026-03-18*
+*Source: 2026-03-18-starship-flight12-v3-status | Added: 2026-03-18*
 
 While competitors close the reusability gap (per 2026-03-11 findings), V3 widens the capability gap through 3x payload increase. This creates a two-dimensional competition space where reusability becomes table stakes but payload capacity determines strategic positioning. V3 at 100+ tonnes LEO moves Starship into a capability tier no competitor has announced plans to reach.
 

domains/space-development/sda-pwsa-operational-battle-management-establishes-defense-as-first-deployed-orbital-computing-user.md

@@ -11,9 +11,9 @@ scope: structural
 sourcer: National Defense Magazine
 related_claims: ["[[defense spending is the new catalyst for space investment with US Space Force budget jumping 39 percent in one year to 40 billion]]", "[[space governance gaps are widening not narrowing because technology advances exponentially while institutional design advances linearly]]"]
 supports:
-  - "Golden Dome missile defense requires orbital compute because ground-based processing transmission latency exceeds time-critical decision windows for missile interception"
+- Golden Dome missile defense requires orbital compute because ground-based processing transmission latency exceeds time-critical decision windows for missile interception
 reweave_edges:
-  - "Golden Dome missile defense requires orbital compute because ground-based processing transmission latency exceeds time-critical decision windows for missile interception|supports|2026-04-04"
+- Golden Dome missile defense requires orbital compute because ground-based processing transmission latency exceeds time-critical decision windows for missile interception|supports|2026-04-04
 ---
 
 # The Space Development Agency's PWSA is already running battle management algorithms in space as an operational capability, establishing defense as the first deployed user of orbital computing at constellation scale

domains/space-development/space-based computing at datacenter scale is blocked by thermal physics because radiative cooling in vacuum requires surface areas that grow faster than compute density.md

@@ -8,16 +8,16 @@ created: 2026-02-17
 secondary_domains:
   - critical-systems
 depends_on:
-  - "Starship achieving routine operations at sub-100 dollars per kg is the single largest enabling condition for the entire space industrial economy"
+- Starship achieving routine operations at sub-100 dollars per kg is the single largest enabling condition for the entire space industrial economy
-  - "power is the binding constraint on all space operations because every capability from ISRU to manufacturing to life support is power-limited"
+- power is the binding constraint on all space operations because every capability from ISRU to manufacturing to life support is power-limited
 related:
-  - "Orbital data center thermal management is a scale-dependent engineering challenge not a hard physics constraint with passive cooling sufficient at CubeSat scale and tractable solutions at megawatt scale"
+- Orbital data center thermal management is a scale-dependent engineering challenge not a hard physics constraint with passive cooling sufficient at CubeSat scale and tractable solutions at megawatt scale
-  - "Radiative cooling in space is a cost advantage over terrestrial data centers, not merely a constraint to overcome, with claimed cooling costs of $0.002-0.005/kWh versus terrestrial active cooling"
+- Radiative cooling in space is a cost advantage over terrestrial data centers, not merely a constraint to overcome, with claimed cooling costs of $0.002-0.005/kWh versus terrestrial active cooling
-  - "solar irradiance in LEO delivers 8 10x ground based solar power with near continuous availability in sun synchronous orbits making orbital compute power abundant where terrestrial facilities are power starved"
+- solar irradiance in LEO delivers 8 10x ground based solar power with near continuous availability in sun synchronous orbits making orbital compute power abundant where terrestrial facilities are power starved
 reweave_edges:
-  - "Orbital data center thermal management is a scale-dependent engineering challenge not a hard physics constraint with passive cooling sufficient at CubeSat scale and tractable solutions at megawatt scale|related|2026-04-04"
+- Orbital data center thermal management is a scale-dependent engineering challenge not a hard physics constraint with passive cooling sufficient at CubeSat scale and tractable solutions at megawatt scale|related|2026-04-04
-  - "Radiative cooling in space is a cost advantage over terrestrial data centers, not merely a constraint to overcome, with claimed cooling costs of $0.002-0.005/kWh versus terrestrial active cooling|related|2026-04-04"
+- Radiative cooling in space is a cost advantage over terrestrial data centers, not merely a constraint to overcome, with claimed cooling costs of $0.002-0.005/kWh versus terrestrial active cooling|related|2026-04-04
-  - "solar irradiance in LEO delivers 8 10x ground based solar power with near continuous availability in sun synchronous orbits making orbital compute power abundant where terrestrial facilities are power starved|related|2026-04-04"
+- solar irradiance in LEO delivers 8 10x ground based solar power with near continuous availability in sun synchronous orbits making orbital compute power abundant where terrestrial facilities are power starved|related|2026-04-04
 ---
 
 # Space-based computing at datacenter scale is blocked by thermal physics because radiative cooling in vacuum requires surface areas that grow faster than compute density
@@ -45,4 +45,4 @@ Relevant Notes:
 - [[distributed LEO inference networks could serve global AI requests at 4-20ms latency competitive with centralized terrestrial data centers for latency-tolerant workloads]] — the viable long-term use case
 
 Topics:
-- [[space exploration and development]]
+- space exploration and development

domains/space-development/space-based pharmaceutical manufacturing produces clinically superior drug formulations that cannot be replicated on Earth.md

@@ -8,12 +8,12 @@ created: 2026-02-17
 secondary_domains:
   - health
 depends_on:
-  - "microgravity eliminates convection sedimentation and container effects producing measurably superior materials across fiber optics pharmaceuticals and semiconductors"
+- microgravity eliminates convection sedimentation and container effects producing measurably superior materials across fiber optics pharmaceuticals and semiconductors
-  - "microgravity-discovered pharmaceutical polymorphs are a novel IP mechanism because new crystal forms enable patent extension reformulation and new delivery methods"
+- microgravity-discovered pharmaceutical polymorphs are a novel IP mechanism because new crystal forms enable patent extension reformulation and new delivery methods
 supports:
-  - "Varda Space Industries validates commercial space manufacturing with four orbital missions 329M raised and monthly launch cadence by 2026"
+- Varda Space Industries validates commercial space manufacturing with four orbital missions 329M raised and monthly launch cadence by 2026
 reweave_edges:
-  - "Varda Space Industries validates commercial space manufacturing with four orbital missions 329M raised and monthly launch cadence by 2026|supports|2026-04-04"
+- Varda Space Industries validates commercial space manufacturing with four orbital missions 329M raised and monthly launch cadence by 2026|supports|2026-04-04
 ---
 
 # Space-based pharmaceutical manufacturing produces clinically superior drug formulations that cannot be replicated on Earth
@@ -42,4 +42,4 @@ Relevant Notes:
 - [[microgravity-discovered pharmaceutical polymorphs are a novel IP mechanism because new crystal forms enable patent extension reformulation and new delivery methods]] — the specific IP mechanism
 
 Topics:
-- [[space exploration and development]]
+- space exploration and development

domains/space-development/spacetech-series-a-funding-gap-is-the-structural-bottleneck-because-specialized-vcs-concentrate-at-seed-while-generalists-lack-domain-expertise-for-hardware-companies.md

@@ -6,11 +6,12 @@ confidence: likely
 source: "Astra, Space Ambition / Beyond Earth Technologies 2024 deal analysis (65 deals >$5M)"
 created: 2026-03-23
 secondary_domains: ["manufacturing"]
-challenged_by: ["growing institutional interest (Axiom $350M, CesiumAstro $270M in early 2026) may be closing the gap as the sector matures"]
+challenged_by:
+- growing institutional interest (Axiom $350M, CesiumAstro $270M in early 2026) may be closing the gap as the sector matures
 related:
-  - "aesthetic futurism in deeptech vc kills companies through narrative shifts not technology failure because investors skip engineering arithmetic for vision driven bets"
+- aesthetic futurism in deeptech vc kills companies through narrative shifts not technology failure because investors skip engineering arithmetic for vision driven bets
 reweave_edges:
-  - "aesthetic futurism in deeptech vc kills companies through narrative shifts not technology failure because investors skip engineering arithmetic for vision driven bets|related|2026-04-04"
+- aesthetic futurism in deeptech vc kills companies through narrative shifts not technology failure because investors skip engineering arithmetic for vision driven bets|related|2026-04-04
 ---
 
 # SpaceTech Series A+ funding gap is the structural bottleneck because specialized VCs concentrate at seed while generalists lack domain expertise for hardware companies

domains/space-development/ten percent of near-Earth asteroids are more energetically accessible than the lunar surface with some requiring less delta-v than a soft Moon landing.md

@@ -6,11 +6,11 @@ confidence: likely
 source: "Astra, web research compilation February 2026; orbital mechanics literature"
 created: 2026-02-17
 depends_on:
-  - "asteroid mining economics split into three distinct business models with water-for-propellant viable near-term and metals-for-Earth-return decades away"
+- asteroid mining economics split into three distinct business models with water-for-propellant viable near-term and metals-for-Earth-return decades away
 supports:
-  - "asteroid mining and orbital habitats should be prioritized over planetary colonization because gravity wells are the binding constraint on opening the solar system to humanity"
+- asteroid mining and orbital habitats should be prioritized over planetary colonization because gravity wells are the binding constraint on opening the solar system to humanity
 reweave_edges:
-  - "asteroid mining and orbital habitats should be prioritized over planetary colonization because gravity wells are the binding constraint on opening the solar system to humanity|supports|2026-04-04"
+- asteroid mining and orbital habitats should be prioritized over planetary colonization because gravity wells are the binding constraint on opening the solar system to humanity|supports|2026-04-04
 ---
 
 # Ten percent of near-Earth asteroids are more energetically accessible than the lunar surface with some requiring less delta-v than a soft Moon landing
@@ -38,4 +38,4 @@ Relevant Notes:
 - [[the Moon serves as a proving ground for Mars settlement because 2-day transit enables 180x faster iteration cycles than the 6-month Mars journey]] — lunar proximity advantage offsets asteroid energy advantage for development iteration
 
 Topics:
-- [[space exploration and development]]
+- space exploration and development

domains/space-development/the Artemis Accords replace multilateral treaty-making with bilateral norm-setting to create governance through coalition practice rather than universal consensus.md

@@ -5,11 +5,12 @@ description: "61 nations signed bilateral accords establishing resource extracti
 confidence: likely
 source: "Artemis Accords text (2020), signatory count (61 as of January 2026), US State Department bilateral framework, comparison with Moon Agreement ratification failure"
 created: 2026-03-08
-challenged_by: "The Accords may be less durable than treaties because they lack binding enforcement. If a signatory violates safety zone norms or resource extraction principles, no mechanism compels compliance. The bilateral structure also means each agreement is slightly different, creating potential inconsistencies that multilateral treaties avoid. And the China/Russia exclusion creates a bifurcated governance regime that could escalate into resource conflicts at contested sites like the lunar south pole."
+challenged_by:
+- The Accords may be less durable than treaties because they lack binding enforcement. If a signatory violates safety zone norms or resource extraction principles, no mechanism compels compliance. The bilateral structure also means each agreement is slightly different, creating potential inconsistencies that multilateral treaties avoid. And the China/Russia exclusion creates a bifurcated governance regime that could escalate into resource conflicts at contested sites like the lunar south pole.
 supports:
-  - "lunar development is bifurcating into two competing governance blocs that mirror terrestrial geopolitical alignment"
+- lunar development is bifurcating into two competing governance blocs that mirror terrestrial geopolitical alignment
 reweave_edges:
-  - "lunar development is bifurcating into two competing governance blocs that mirror terrestrial geopolitical alignment|supports|2026-04-04"
+- lunar development is bifurcating into two competing governance blocs that mirror terrestrial geopolitical alignment|supports|2026-04-04
 ---
 
 # the Artemis Accords replace multilateral treaty-making with bilateral norm-setting to create governance through coalition practice rather than universal consensus

domains/space-development/the Moon serves as a proving ground for Mars settlement because 2-day transit enables 180x faster iteration cycles than the 6-month Mars journey.md

@@ -5,11 +5,12 @@ description: "SpaceX pivoted near-term focus from Mars to Moon in February 2026
 confidence: likely
 source: "Astra, SpaceX announcements and web research February 2026"
 created: 2026-03-20
-challenged_by: ["lunar environment differs fundamentally from Mars — 1/6g vs 1/3g, no atmosphere, different regolith chemistry — so lunar-proven systems may need significant redesign for Mars"]
+challenged_by:
+- lunar environment differs fundamentally from Mars — 1/6g vs 1/3g, no atmosphere, different regolith chemistry — so lunar-proven systems may need significant redesign for Mars
 related:
-  - "lunar resource extraction economics require equipment mass ratios under 50 tons per ton of mined material at projected 1M per ton delivery costs"
+- lunar resource extraction economics require equipment mass ratios under 50 tons per ton of mined material at projected 1M per ton delivery costs
 reweave_edges:
-  - "lunar resource extraction economics require equipment mass ratios under 50 tons per ton of mined material at projected 1M per ton delivery costs|related|2026-04-04"
+- lunar resource extraction economics require equipment mass ratios under 50 tons per ton of mined material at projected 1M per ton delivery costs|related|2026-04-04
 ---
 
 # The Moon serves as a proving ground for Mars settlement because 2-day transit enables 180x faster iteration cycles than the 6-month Mars journey

domains/space-development/the commercial space station transition from ISS creates a gap risk that could end 25 years of continuous human presence in low Earth orbit.md

@@ -6,11 +6,11 @@ confidence: likely
 source: "Astra, web research compilation February 2026"
 created: 2026-02-17
 depends_on:
-  - "commercial space stations are the next infrastructure bet as ISS retirement creates a void that 4 companies are racing to fill by 2030"
+- commercial space stations are the next infrastructure bet as ISS retirement creates a void that 4 companies are racing to fill by 2030
 related:
-  - "Vast is building the first commercial space station with Haven 1 launching 2027 funded by Jed McCaleb 1B personal commitment and targeting artificial gravity stations by the 2030s"
+- Vast is building the first commercial space station with Haven 1 launching 2027 funded by Jed McCaleb 1B personal commitment and targeting artificial gravity stations by the 2030s
 reweave_edges:
-  - "Vast is building the first commercial space station with Haven 1 launching 2027 funded by Jed McCaleb 1B personal commitment and targeting artificial gravity stations by the 2030s|related|2026-04-04"
+- Vast is building the first commercial space station with Haven 1 launching 2027 funded by Jed McCaleb 1B personal commitment and targeting artificial gravity stations by the 2030s|related|2026-04-04
 ---
 
 # The commercial space station transition from ISS creates a gap risk that could end 25 years of continuous human presence in low Earth orbit
@@ -37,4 +37,4 @@ Relevant Notes:
 - [[Axiom Space has the strongest operational position for commercial orbital habitation but the weakest financial position among funded competitors]] — Axiom's financial instability is the single largest risk factor
 
 Topics:
-- [[space exploration and development]]
+- space exploration and development

domains/space-development/the space launch cost trajectory is a phase transition not a gradual decline analogous to sail-to-steam in maritime transport.md

@@ -6,15 +6,15 @@ confidence: likely
 source: "Astra, web research compilation February 2026"
 created: 2026-02-17
 depends_on:
-  - "launch cost reduction is the keystone variable that unlocks every downstream space industry at specific price thresholds"
+- launch cost reduction is the keystone variable that unlocks every downstream space industry at specific price thresholds
-  - "good management causes disruption because rational resource allocation systematically favors sustaining innovation over disruptive opportunities"
+- good management causes disruption because rational resource allocation systematically favors sustaining innovation over disruptive opportunities
 secondary_domains:
   - teleological-economics
   - critical-systems
 supports:
-  - "europe space launch strategic irrelevance without starship class capability"
+- europe space launch strategic irrelevance without starship class capability
 reweave_edges:
-  - "europe space launch strategic irrelevance without starship class capability|supports|2026-04-04"
+- europe space launch strategic irrelevance without starship class capability|supports|2026-04-04
 ---
 
 # the space launch cost trajectory is a phase transition not a gradual decline analogous to sail-to-steam in maritime transport
@@ -31,20 +31,20 @@ Phase transition framing implies inevitability, but the transition requires sust
 
 
 ### Additional Evidence (confirm)
-*Source: [[2026-03-00-phys-org-europe-answer-to-starship]] | Added: 2026-03-12 | Extractor: anthropic/claude-sonnet-4.5*
+*Source: 2026-03-00-phys-org-europe-answer-to-starship | Added: 2026-03-12 | Extractor: anthropic/claude-sonnet-4.5*
 
 Europe's institutional response to the reusability revolution demonstrates the phase-transition nature of the shift. The German Aerospace Center's assessment that "Europe is toast without a Starship clone" frames this as a binary strategic divide, not a gradual improvement curve. Europe has three separate reusable launch concepts under development (RLV C5, SUSIE, ESA/Avio), yet all remain in early design phase with no operational timelines as of March 2026. Meanwhile, Ariane 6—which first flew in 2024 as an expendable vehicle—is already assessed as strategically obsolete by Europe's own institutions. This is not a case of Europe being slightly behind on a continuous improvement trajectory; it's a recognition that the competitive structure has fundamentally changed and incremental improvements won't close the gap. The fact that SUSIE is explicitly characterized as "catching up with current US capabilities, not competing with next-gen" reinforces that this is a discrete phase transition where being in the wrong era creates strategic irrelevance.
 
 
 ### Additional Evidence (confirm)
-*Source: [[2026-03-18-starship-flight12-v3-status]] | Added: 2026-03-18*
+*Source: 2026-03-18-starship-flight12-v3-status | Added: 2026-03-18*
 
 V3's 3x payload jump from V2 (35t to 100+ tonnes) within a single vehicle generation exemplifies discontinuous capability improvement characteristic of phase transitions. The 30-minute propellant loading time for B19 and accumulated 40,000+ seconds of Raptor 3 testing show operational maturation accelerating alongside performance gains, compressing the transition timeline.
 
 ---
 
 ### Additional Evidence (extend)
-*Source: [[2026-xx-richmondfed-rural-electrification-two-gate-analogue]] | Added: 2026-03-24*
+*Source: 2026-xx-richmondfed-rural-electrification-two-gate-analogue | Added: 2026-03-24*
 
 Rural electrification provides a second phase-transition analogue: supply threshold crossed quietly in the 1910s-1920s (urban electrification), demand threshold crossed suddenly with REA catalyst in 1936, then rapid adoption (400 miles of REA lines in 1936 → 115,230 miles by 1939). The transition pattern is supply readiness + catalytic intervention + rapid scaling, not gradual linear adoption.
 

domains/space-development/varda-space-biologics-development-blurs-three-tier-manufacturing-sequence.md

@@ -6,13 +6,14 @@ description: "Varda's monoclonal antibody processing starting in 2026 suggests c
 confidence: experimental
 source: "Varda Space Industries PR (2026-01-29), new biologics lab opening"
 created: 2026-01-29
-depends_on: ["the space manufacturing killer app sequence is pharmaceuticals now ZBLAN fiber in 3-5 years and bioprinted organs in 15-25 years each catalyzing the next tier of orbital infrastructure"]
+depends_on:
+- the space manufacturing killer app sequence is pharmaceuticals now ZBLAN fiber in 3-5 years and bioprinted organs in 15-25 years each catalyzing the next tier of orbital infrastructure
 related:
-  - "Varda Space Industries validates commercial space manufacturing with four orbital missions 329M raised and monthly launch cadence by 2026"
+- Varda Space Industries validates commercial space manufacturing with four orbital missions 329M raised and monthly launch cadence by 2026
-  - "varda vertical integration reduces space manufacturing access costs"
+- varda vertical integration reduces space manufacturing access costs
 reweave_edges:
-  - "Varda Space Industries validates commercial space manufacturing with four orbital missions 329M raised and monthly launch cadence by 2026|related|2026-04-04"
+- Varda Space Industries validates commercial space manufacturing with four orbital missions 329M raised and monthly launch cadence by 2026|related|2026-04-04
-  - "varda vertical integration reduces space manufacturing access costs|related|2026-04-04"
+- varda vertical integration reduces space manufacturing access costs|related|2026-04-04
 ---
 
 # Varda's biologics development suggests companies may pursue parallel tier development in space manufacturing
@@ -40,4 +41,4 @@ Relevant Notes:
 - [[microgravity eliminates convection sedimentation and container effects producing measurably superior materials across fiber optics pharmaceuticals and semiconductors]] <!-- claim pending -->
 
 Topics:
-- [[domains/space-development/_map]]
+- domains/space-development/_map

domains/space-development/varda-vertical-integration-reduces-space-manufacturing-access-costs.md

@@ -5,11 +5,12 @@ description: "In-house satellite bus and heatshield production enables Varda to
 confidence: experimental
 source: "Varda Space Industries W-5 mission (2026-01-29), vertical integration debut"
 created: 2026-01-29
-depends_on: ["SpaceX vertical integration across launch broadband and manufacturing creates compounding cost advantages that no competitor can replicate piecemeal"]
+depends_on:
+- SpaceX vertical integration across launch broadband and manufacturing creates compounding cost advantages that no competitor can replicate piecemeal
 supports:
-  - "Varda Space Industries validates commercial space manufacturing with four orbital missions 329M raised and monthly launch cadence by 2026"
+- Varda Space Industries validates commercial space manufacturing with four orbital missions 329M raised and monthly launch cadence by 2026
 reweave_edges:
-  - "Varda Space Industries validates commercial space manufacturing with four orbital missions 329M raised and monthly launch cadence by 2026|supports|2026-04-04"
+- Varda Space Industries validates commercial space manufacturing with four orbital missions 329M raised and monthly launch cadence by 2026|supports|2026-04-04
 ---
 
 # Varda's vertical integration of satellite bus and ablative heatshield enables cost reduction and accelerated iteration in reentry vehicle design
@@ -32,7 +33,7 @@ This claim infers cost reduction from vertical integration and cadence accelerat
 
 
 ### Additional Evidence (confirm)
-*Source: [[2026-03-18-varda-w5-vertically-integrated-bus]] | Added: 2026-03-18*
+*Source: 2026-03-18-varda-w5-vertically-integrated-bus | Added: 2026-03-18*
 
 Varda W-5 mission (January 2026) successfully deployed first vertically integrated satellite bus and in-house manufactured C-PICA heatshield, completing full mission lifecycle control. This is the 5th mission (4 in 2025 alone), demonstrating the vertical integration thesis is now operational at scale, not theoretical.
 
@@ -43,4 +44,4 @@ Relevant Notes:
 - [[launch cost reduction is the keystone variable that unlocks every downstream space industry at specific price thresholds]]
 
 Topics:
-- [[domains/space-development/_map]]
+- domains/space-development/_map

entities/space-development/starcloud.md

@@ -9,6 +9,12 @@ industry: orbital data centers, space-based AI compute
 key_people: []
 website: []
 tags: [orbital-data-center, AI-compute, small-satellite, NVIDIA-partnership, SpaceX-rideshare]
+supports:
+- Starcloud is the first company to operate a datacenter grade GPU in orbit but faces an existential dependency on SpaceX for launches while SpaceX builds a competing million satellite constellation
+- Orbital data center deployment follows a three-tier launch vehicle activation sequence (rideshare → dedicated → constellation) where each tier unlocks an order-of-magnitude increase in compute scale
+reweave_edges:
+- Starcloud is the first company to operate a datacenter grade GPU in orbit but faces an existential dependency on SpaceX for launches while SpaceX builds a competing million satellite constellation|supports|2026-04-04
+- Orbital data center deployment follows a three-tier launch vehicle activation sequence (rideshare → dedicated → constellation) where each tier unlocks an order-of-magnitude increase in compute scale|supports|2026-04-04
 ---
 
 # Starcloud